

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

Set	Items	Description
S1	2941874	TRACK? OR TRACE? OR TRACING OR MONITOR?
S2	419717	(CLINICAL? OR MEDICAL) (5N) (STUDIES OR STUDY OR RESEARCH? OR TRIAL?)
S3	5366	S1(5N)S2
S4	240	S3(15N) (SAMPLE? OR EXHIBIT? OR BLOOD? OR SERUM OR GENOTYP? OR PHENOTYP?)
S5	100	S4 NOT PY>1999
S6	61	RD (unique items)

? show files

File 9:Business & Industry(R) Jul/1994-2003/Apr 24  
(c) 2003 Resp. DB Svcs.

File 15:ABI/Inform(R) 1971-2003/Apr 25  
(c) 2003 ProQuest Info&Learning

File 16:Gale Group PROMT(R) 1990-2003/Apr 24  
(c) 2003 The Gale Group

File 148:Gale Group Trade & Industry DB 1976-2003/Apr 24  
(c)2003 The Gale Group

File 160:Gale Group PROMT(R) 1972-1989  
(c) 1999 The Gale Group

File 275:Gale Group Computer DB(TM) 1983-2003/Apr 24  
(c) 2003 The Gale Group

File 621:Gale Group New Prod.Annou.(R) 1985-2003/Apr 24  
(c) 2003 The Gale Group

File 636:Gale Group Newsletter DB(TM) 1987-2003/Apr 24  
(c) 2003 The Gale Group

6/3,K/1 (Item 1 from file: 9)  
DIALOG(R)File 9:Business & Industry(R)  
(c) 2003 Resp. DB Svcs. All rts. reserv.

2605373 Supplier Number: 02605373 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Diabetes Immunotherapy Clinical Trial Studies Nicotinamide for Diabetes**  
**(Italian study finds Nicotinamide (NA) can be beneficial to patients with**  
**recent-onset Type 1 diabetes)**  
World Disease Weekly Plus, p N/A  
September 27, 1999  
DOCUMENT TYPE: Newsletter (United States)  
LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 443

(USE FORMAT 7 OR 9 FOR FULLTEXT)

TEXT:

...carried out to optimize metabolic control as soon as possible after diagnosis and to maintain **blood** glucose level as near to normal as possible. Patient response to therapy was **monitored** throughout the **study** by investigating the occurrence of **clinical** (complete) remission defined, according to the recommendations of the International Diabetes Immunotherapy Group without any...

6/3,K/2 (Item 2 from file: 9)  
DIALOG(R)File 9:Business & Industry(R)  
(c) 2003 Resp. DB Svcs. All rts. reserv.

2383152 Supplier Number: 02383152 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Lovenox now available for acute deep-vein thrombosis treatment**  
**(FDA approved Lovenox as first low-molecular weight heparin for outpatient**  
**treatment of acute deep-vein thrombosis without pulmonary embolism)**  
Drug Store News, v 21, n 3, p CP10  
February 15, 1999  
DOCUMENT TYPE: Journal ISSN: 0191-7587 (United States)  
LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 165

(USE FORMAT 7 OR 9 FOR FULLTEXT)

TEXT:

...given to the patient by continuous intravenous infusion, requiring several days of hospitalization and routine **blood** tests to **monitor** drug activity. According to a **study** done at Kaiser Permanente Medical Center, there was a clear economic advantage associated with using Lovenox in the outpatient setting...

6/3,K/3 (Item 3 from file: 9)  
DIALOG(R)File 9:Business & Industry(R)  
(c) 2003 Resp. DB Svcs. All rts. reserv.

2230884 Supplier Number: 02230884 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Never richer**  
**(An estimated 37 drug delivery products await approval; table lists**  
**upcoming drug delivery products with blockbuster potentials)**  
Med Ad News, v 17, n 8, p 38  
August 1998  
DOCUMENT TYPE: Journal ISSN: 0745-0907 (United States)

LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 3272

(USE FORMAT 7 OR 9 FOR FULLTEXT)

TEXT:

...generate at least \$100 million. Worn like a wristwatch, the GlucoWatch system is a painless, **bloodless**, and automatic glucose **monitoring** device. Cygnus moved into registration **clinical trials** with GlucoWatch at the end of 1997; the data from these trials are expected to...

6/3,K/4 (Item 4 from file: 9)  
DIALOG(R)File 9:Business & Industry(R)  
(c) 2003 Resp. DB Svcs. All rts. reserv.

1229381 Supplier Number: 01229381 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Chiron's pipeline**  
**(Chiron Biocine's Gp120 anti-HIV vaccine is in Phase II clinical trials in the US)**  
Med Ad News, v 14, n 7, p 20  
July 1995  
DOCUMENT TYPE: Journal ISSN: 0745-0907 (United States)  
LANGUAGE: English RECORD TYPE: Fulltext  
WORD COUNT: 616

(USE FORMAT 7 OR 9 FOR FULLTEXT)

TEXT:

...U.S. preclinical trials.

CMV bDNA Probe Test is being studied for quantifying viruses.

Critical **blood** analytes are in preclinical studies for **monitoring** critical care patients.

Discontinued **clinical trials**  
Macrolin (macrophage colony stimulating factor) was in Phase III clinical trials in the United States...

6/3,K/5 (Item 1 from file: 15)  
DIALOG(R)File 15:ABI/Inform(R)  
(c) 2003 ProQuest Info&Learning. All rts. reserv.

01170603 98-19998  
**A community case management model**  
Faress, Mary Lynn  
Nursing Management v27n3 PP: 65-66 Mar 1996  
ISSN: 0744-6314 JRNL CODE: NSM  
WORD COUNT: 651

...TEXT: admission compared to data before we implemented Care-Link Health status outcome measurements include (diabetic) **blood** glucose data, complication rates and co-morbidity **tracking**. Qualitative data encompass patient satisfaction **studies**.

Care-Link provides valuable expanded **clinical** opportunities for BSN students undergoing their community health rotation. The nursing faculty is currently considering...

6/3,K/6 (Item 2 from file: 15)  
DIALOG(R)File 15:ABI/Inform(R)  
(c) 2003 ProQuest Info&Learning. All rts. reserv.

00610156 92-25259  
**OSHA Targets AIDS in the Workplace**  
Kurland, Orin M.  
Risk Management v39n4 PP: 16-18 Apr 1992  
ISSN: 0035-5593 JRNL CODE: RMT  
WORD COUNT: 1394

...TEXT: bundle of gauze and wrappers on the bed of an AIDS patient after taking a **blood** culture."

The February issue of the " **Medical Liability Monitor** " reported **research** suggesting that 88 percent of needlesticks are preventable. This finding simply further demonstrates the added...

6/3,K/7 (Item 1 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

08296274 Supplier Number: 66680037 (USE FORMAT 7 FOR FULLTEXT)  
**Phase III Clinical Development.**  
BioPharm, pS18  
Dec, 1999  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 1503

... subjects involved in a Phase III study depends on the disease being studied. Phase III **trials** are expensive: **Clinical monitoring** of patients can include X-rays, **blood** tests, and other laboratory studies in addition to physician fees and required hospitalizations. Whereas classical ...

6/3,K/8 (Item 2 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06850731 Supplier Number: 58033233 (USE FORMAT 7 FOR FULLTEXT)  
**New SND Solutions Framework Offers Business-Driven Applications To Extend the Functionality of Sales Automation Systems.**  
PR Newswire, p5422  
Dec 6, 1999  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 386

... Solutions Framework  
SND Solutions Framework delivers a complete platform of application modules, including Marketing Budget **Tracking**, **Sample** Allocation, **Clinical Trials** Management, and Literature Ordering, that can be enhanced to support client-specific business processes. The...

6/3,K/9 (Item 3 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06759895 Supplier Number: 55982143 (USE FORMAT 7 FOR FULLTEXT)  
**Clinical Trial Studies Nicotinamide for Diabetes.(Statistical Data Included)**

Marble, Michelle  
World Disease Weekly Plus, pNA  
Sept 27, 1999  
Language: English Record Type: Fulltext  
Article Type: Statistical Data Included  
Document Type: Newsletter; Professional Trade  
Word Count: 447

... carried out to optimize metabolic control as soon as possible after diagnosis and to maintain **blood** glucose level as near to normal as possible. Patient response to therapy was **monitored** throughout the **study** by investigating the occurrence of **clinical** (complete) remission defined, according to the recommendations of the International Diabetes Immunotherapy Group without any...

6/3,K/10 (Item 4 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06682519 Supplier Number: 55918625 (USE FORMAT 7 FOR FULLTEXT)  
**Micrologix initiates phase II clinical trials of MBI 226.**  
PR Newswire, p6263  
Sept 30, 1999  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 625

... counter)  
Micrologix is pleased to announce the commencement of a two-part US Phase II **clinical trial** as part of the fast **track** development program of MBI 226 for the prevention of central venous catheter-related **bloodstream** infection. The trial, developed in consultation with the US Food & Drug Administration (FDA), is designed...

6/3,K/11 (Item 5 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06454940 Supplier Number: 55082223 (USE FORMAT 7 FOR FULLTEXT)  
**Firm's technology takes the work out of blood work. (VIA Medical Corp.)**  
Webb, Marion  
San Diego Business Journal, v20, n25, p1(2)  
June 21, 1999  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Tabloid; Trade  
Word Count: 1261

... newborns, named VIA low-volume mode (LVM) neonatal systems.  
Billman, who headed the 12-month **clinical trial** for the **blood** gas **monitoring** system at Children's Hospital and holds a stake in the firm, touts the device...

6/3,K/12 (Item 6 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06444599 Supplier Number: 55018249 (USE FORMAT 7 FOR FULLTEXT)  
**Varian, Inc. Signs \$6 Million Sales Agreement With Seiko Instruments Inc.**  
**'SII'; SII to Resell Analytical Instrument Line in Japan.**  
Business Wire, p0093  
June 29, 1999  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 417

... for measuring the concentrations of a wide range of chemical elements in a variety of **samples**. Major applications include environmental **monitoring**, life science and **clinical studies**, industrial quality assurance, geo-chemical exploration, and metallurgical analysis.

Varian, Inc.'s Vista system is...

6/3,K/13 (Item 7 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06327555 Supplier Number: 54592484 (USE FORMAT 7 FOR FULLTEXT)  
**Strategic Network Designs Launches Vertical Market Practice to Provide**  
**Sales Automation Solutions to the Pharmaceutical Industry.**  
Business Wire, p1106  
May 10, 1999  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 656

... especially for the pharmaceutical industry. Working from a standard model, SND has developed solutions for **Sample Ordering**, **Literature Ordering**, **Clinical Trials Management** and **Marketing Budget Tracking** systems. This application model enables SND to provide clients with economies of scale in implementation...

6/3,K/14 (Item 8 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06185209 Supplier Number: 54073039 (USE FORMAT 7 FOR FULLTEXT)  
**PE Biosystems Introduces System to Rapidly Identify Drug-Resistant HIV**  
**Strains.**  
Business Wire, p1056  
March 11, 1999  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 715

(USE FORMAT 7 FOR FULLTEXT)  
TEXT:  
...complete, automated system for standardized, sequence-based genotyping of resistance mutations in HIV. The HIV **Genotyping** System is expected to

be of immediate use in investigational **clinical trials** to monitor the development of drug-resistant HIV strains and assess the effectiveness of anti-HIV drugs...

6/3,K/15 (Item 9 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

06117437 Supplier Number: 53723431 (USE FORMAT 7 FOR FULLTEXT)  
**Enoxaparin cleared to treat DVT at home, in hospital.(deep-vein thrombosis)**  
Levy, Sandra  
Drug Topics, v143, n2, p56(1)  
Feb 1, 1999  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 706

... heparin, given by continuous intravenous infusion. This requires several days of hospitalization along with routine **blood tests** to **monitor** drug activity.

Two **clinical trials** comparing enoxaparin with unfractionated heparin found enoxaparin equivalent to adjusted-dose, continuous-infusion therapy with...

6/3,K/16 (Item 10 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

05896708 Supplier Number: 53099981 (USE FORMAT 7 FOR FULLTEXT)  
**First Consumer Advertising Campaign for Prescription Weight-Management Product Launched.**  
PR Newswire, p4791  
Oct 20, 1998  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 1634

... include dry mouth, headache, insomnia and constipation. Some people taking MERIDIA experienced substantial increases in **blood pressure** and heart rate. Regular **blood pressure monitoring** is required when prescribing MERIDIA. **Clinical studies** showed that these **blood pressure** and heart rate increases generally occur early on in treatment and the prescribing physician...

6/3,K/17 (Item 11 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

05769071 Supplier Number: 50256765 (USE FORMAT 7 FOR FULLTEXT)  
**EFFEXOR SAVES COSTS IN TREATING MAJOR DEPRESSION**  
Worldwide Biotech, v10, n9, pN/A  
Sept 1, 1998  
Language: English Record Type: Fulltext  
Article Type: Article  
Document Type: Newsletter; Trade  
Word Count: 851



... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in **blood pressure** in some patients, so regular **blood -pressure monitoring** is recommended. In **clinical trials** of Effexor XR, the overall incidence of sustained increases in **blood pressure** was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/18 (Item 12 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

05711342 Supplier Number: 50172306 (USE FORMAT 7 FOR FULLTEXT)  
**Studies Show That the Antidepressant Effexor(R) XR Also Provides Effective Relief of Anxiety Symptoms**  
PR Newswire, p715NYW019  
July 15, 1998  
Language: English Record Type: Fulltext  
Article Type: Article  
Document Type: Newswire; Trade  
Word Count: 767

... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in **blood pressure** in some patients, so regular **blood -pressure monitoring** is recommended. In **clinical trials** of Effexor XR, the overall incidence of sustained increases in **blood pressure** was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/19 (Item 13 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

05706968 Supplier Number: 50164641 (USE FORMAT 7 FOR FULLTEXT)  
**Study Demonstrates That Effexor Saves Costs in Treating Major Depression.**  
Business Wire, p7131187  
July 13, 1998  
Language: English Record Type: Fulltext  
Article Type: Article  
Document Type: Newswire; Trade  
Word Count: 888

... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in **blood pressure** in some patients, so regular **blood -pressure monitoring** is recommended. In **clinical trials** of Effexor XR, the overall incidence of sustained increases in **blood pressure** was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/20 (Item 14 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04816408 Supplier Number: 47085524 (USE FORMAT 7 FOR FULLTEXT)  
**OMRON INTRODUCES WORLD'S SMALLEST BLOOD PRESSURE MONITOR**  
Biotech Equipment Update, v5, n2, pN/A  
Feb 1, 1997  
Language: English Record Type: Fulltext

Document Type: Newsletter; Trade  
Word Count: 222

... numbers on the front of the unit.  
Created by the market's leading manufacturer of **blood pressure monitors** and based on **clinical research** that has proven a direct relationship between **blood pressure** in the finger and the arm, the product is useful for those who need...

6/3,K/21 (Item 15 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04764619 Supplier Number: 47013900 (USE FORMAT 7 FOR FULLTEXT)  
**World's smallest blood pressure monitor; goes where you go, lets your finger do the "talking".**  
Business Wire, p1061488  
Jan 6, 1997  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 249

... numbers on the front of the unit.  
Created by the market's leading manufacturer of **blood pressure monitors** and based on **clinical research** that has proven a direct relationship between **blood pressure** in the finger and the arm, the product is useful for those who need...

6/3,K/22 (Item 16 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04593827 Supplier Number: 46754396 (USE FORMAT 7 FOR FULLTEXT)  
**Have a Heart**  
Health Data Management, p62  
Oct, 1996  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 1483

... creates images of where the dyes are flowing through the body to identify problems in **blood flow**. The **clinical** system **monitoring** this **study** at a remote hospital creates live video images. New England's telecardiology system captures these...

6/3,K/23 (Item 17 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04078885 Supplier Number: 45940284  
**Biosensors are Making Steady Yet Limited Progress into the Marketplace**  
Genetic Engineering News, p14  
Nov 15, 1995  
Language: English Record Type: Abstract  
Document Type: Magazine/Journal; Trade

ABSTRACT:

...with a sensor in order to detect the quantity of a specific compound in a **sample**. Biosensors are used in **research**, **clinical testing**, **bioprocess monitoring** and environmental testing. Both Pharmacia and Yellow Springs Instrument Co. are offering new products. The...

6/3,K/24 (Item 18 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04010375 Supplier Number: 45825116 (USE FORMAT 7 FOR FULLTEXT)  
**BIOPATH LAUNCHES LABELING AND EVENT TRACKING SYSTEM FOR CLINICAL TRIALS**  
Biotech Equipment Update, v3, n10, pN/A  
Oct 1, 1995  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 381

... flexible. The product was designed specifically to meet the varying needs of pharmaceutical manufacturers during **clinical trial** protocols."  
BioPath's STICS ( **Sample Tracking** and Information Control Systems) is a portfolio of PC-based labeling systems that combine standard...

6/3,K/25 (Item 19 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

03723214 Supplier Number: 45277968 (USE FORMAT 7 FOR FULLTEXT)  
**NORTHFIELD LABORATORIES REPORTS SECOND QUARTER RESULTS**  
PR Newswire, pN/A  
Jan 20, 1995  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 1232

... of blood. There was no evidence of fever, no abnormal changes in heart rate or **blood pressure**, no vasoconstriction and no evidence of organ dysfunction in any recipient.  
"Phase II **clinical trials** continue to progress on **track**," said Richard DeWoskin, Chairman and CEO. "With the success of our initial Phase II trials..."

6/3,K/26 (Item 20 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

03610653 Supplier Number: 45084397 (USE FORMAT 7 FOR FULLTEXT)  
**Epigen plans private placement**  
Biotechnology Business News, pN/A  
Oct 24, 1994  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 81

(USE FORMAT 7 FOR FULLTEXT)  
TEXT:  
...of its common stock in a private placement, and will use proceeds to

begin prospective **clinical trials** of a **blood test** for **monitoring** breast cancer patients. The company said it believes the private placement financing will prompt the...

6/3,K/27 (Item 21 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

03472238 Supplier Number: 44848818 (USE FORMAT 7 FOR FULLTEXT)  
**Treatment STATUS OF IMMUPATH REPORTED AS POTENTIAL AIDS TREATMENT**  
AIDS Weekly, pN/A  
July 18, 1994  
Language: English Record Type: Fulltext  
Document Type: Newsletter; General  
Word Count: 487

... 3). (Decreasing CD4 cell concentrations are indicators of AIDS progression.)

The FDA has approved the **study** 's design, **sample** size, endpoints, **clinical monitoring** and manufacturing plan but has questioned the viral inactivation procedures used in processing Immupath. On...

6/3,K/28 (Item 22 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

03438225 Supplier Number: 44790045 (USE FORMAT 7 FOR FULLTEXT)  
**Treatment News HEMACARE REPORTS ON REGULATORY STATUS OF IMMUPATH**  
AIDS Weekly, pN/A  
June 27, 1994  
Language: English Record Type: Fulltext  
Document Type: Newsletter; General  
Word Count: 473

... CD4 lymphocyte concentrations of 50-200/cells per mm(3).

The FDA has approved the **study** 's design, **sample** size, endpoints, **clinical monitoring** and manufacturing plan but has questioned the viral inactivation procedures used in processing Immupath. On...

6/3,K/29 (Item 23 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

03007576 Supplier Number: 44082083 (USE FORMAT 7 FOR FULLTEXT)  
**U.S. FDA IND GRANTED FOR IMMUNE RECONSTITUTION THERAPY**  
AIDS Weekly, pN/A  
Sept 6, 1993  
Language: English Record Type: Fulltext  
Document Type: Newsletter; General  
Word Count: 212

... it with the FDA within six weeks. The expanded program will be administered as a **monitored clinical trial**," Reiter concluded.

CSI's immune reconstitution therapy includes an infusion of peripheral **blood lymphocytes**, which are specific types of white blood cells deficient in patients with AIDS. An...

6/3,K/30 (Item 24 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

02894016 Supplier Number: 43905281  
**Diabetes Report May Lift Sales of Medical Devices**  
The New York Times, pC4  
June 15, 1993  
Language: English Record Type: Abstract  
Document Type: Newspaper; General

ABSTRACT:  
Complications associated with diabetes could be prevented or delayed by more closely monitoring **blood** sugar levels, according to a new **study**. **Medical** technology companies that make **monitoring** equipment (Lifescan, for example) and insulin delivery systems (Minimed Technologies, for example) might benefit from...

6/3,K/31 (Item 25 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

02745736 Supplier Number: 43676449 (USE FORMAT 7 FOR FULLTEXT)  
**Monitoring HIV Levels**  
Genesis Report-Dx, v2, n5, pN/A  
March, 1993  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 342

... journal Science.  
Researchers at Genelabs Technologies believe the test could be used in therapeutic drug **monitoring** in **clinical trials** of AIDS treatments. By detecting the level of HIV in the **blood**, it could help gauge the effectiveness of antiviral agents in controlling AIDS. Genelabs is using...

6/3,K/32 (Item 26 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

02528654 Supplier Number: 43348785 (USE FORMAT 7 FOR FULLTEXT)  
**T Cell/Yamanouchi marketing deal**  
Biotechnology Business News, pN/A  
Oct 2, 1992  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 329

... candidate, Trax CD4 Test Kit, in the near future. The product is already in late **clinical trials** in the US for **monitoring** white **blood** cells which express the protein receptor, CD4. The main target market for this will be...

6/3,K/33 (Item 27 from file: 16)  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

02209489 Supplier Number: 42878160 (USE FORMAT 7 FOR FULLTEXT)  
**OSHA TARGETS AIDS IN THE WORKPLACE**  
Risk Management, p16  
April, 1992  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 1408

... bundle of gauze and wrappers on the bed of an AIDS patient after taking a **blood** culture."

The February issue of the "**Medical Liability Monitor**" reported **research** suggesting that 88 percent of needlesticks are preventable. This finding simply further demonstrates the added...

**6/3,K/34 (Item 28 from file: 16)**  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

02163769 Supplier Number: 42813312 (USE FORMAT 7 FOR FULLTEXT)  
**NEW PRODUCTS AND SERVICES --**  
Health Business, pN/A  
March 6, 1992  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 250

(USE FORMAT 7 FOR FULLTEXT)  
TEXT:

...astigmatism. The holmium laser system currently is being evaluated to treat farsightedness -- A two-phase **study** finds that use of Wheaton **Medical** Technologies' Medi- **Track** electronic **tracking** system reduces **blood** pressure by enabling patients to follow medication dispensation schedules exactly. Patients using the pocket-sized...

**6/3,K/35 (Item 29 from file: 16)**  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

01831657 Supplier Number: 42315057 (USE FORMAT 7 FOR FULLTEXT)  
**THERMO ELECTRON TO ACQUIRE MANUFACTURER OF HEMOSTASIS MANAGEMENT PRODUCTS**  
PR Newswire, p1  
August 26, 1991  
Language: English Record Type: Fulltext  
Document Type: Newswire; Trade  
Word Count: 230

PRODUCT NAMES: 3841280 (Surgical & **Medical** **Blood** **Monitors** );  
8515200 (Applied **Research** )

**6/3,K/36 (Item 30 from file: 16)**  
DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

01532138 Supplier Number: 41868917 (USE FORMAT 7 FOR FULLTEXT)  
**Centocor's Day in the Sun**  
Health Business, v6, n7, pN/A

Feb 15, 1991  
Language: English      Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 287

... of medical research and the flow of dollars from government and private sources. MRF features **Medical Grant Monitor** detailing every NIH research grant. To order or for a sample call 1-800/848-1153 or 202/828-4150 in Washington DC.

6/3,K/37      (Item 1 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

11358830      SUPPLIER NUMBER: 55807393      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Colour doppler imaging for diagnosis of intracranial hypotension. (Statistical Data Included)**  
Chao-Ching, Chen; Cheau-Lin, Luo; Shuu-Jiun, Wang; Chang-Ming, Chern;  
Jong-Ling, Fuh; Sheng-Han, Lin; Han-Hwa, Hu  
Lancet, 354, 9181, 826  
Sept 4, 1999  
DOCUMENT TYPE: Statistical Data Included      ISSN: 0099-5355  
LANGUAGE: English      RECORD TYPE: Fulltext  
WORD COUNT: 3397      LINE COUNT: 00314

... Moreover, since changes in the blood flow in the superior ophthalmic vein were reversible after **blood** -patch treatment, CDFI would also be useful in **monitoring** the therapeutic effect of **clinical** management. However, this preliminary **study** included only a small number of participants, so further investigations in a larger population are...

6/3,K/38      (Item 2 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

11245071      SUPPLIER NUMBER: 55302919      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Examining garlic's cardiovascular benefits.**  
Drug Store News, 21, 11, 53  
July 19, 1999  
ISSN: 0191-7587      LANGUAGE: English      RECORD TYPE: Fulltext  
WORD COUNT: 362      LINE COUNT: 00032

... aged garlic extract.  
Included in the Wakunaga collection is a meta-analysis of some 16 **clinical trials** conducted between 1987 and 1994, **tracking** the effects of dry aged garlic extract on **blood** lipid levels. Sorting through the results of more than 900 hypercholesterolemic patients, according to the...

6/3,K/39      (Item 3 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

10731428      SUPPLIER NUMBER: 53520315      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**What's new in hypertension: update on angiotensin II receptor blockers. (includes related article on the role of angiotensin II in the development of hypertension)**  
Black, Henry R.

Consultant, 38, 11, 2715(7).

Nov, 1998

ISSN: 0010-7069

LANGUAGE: English

RECORD TYPE: Fulltext; Abstract

WORD COUNT: 3595

LINE COUNT: 00308

... receptor in vitro than losartan is, but it is unclear whether this feature has any **clinical** implications.(15)

EFFICACY

**Clinical studies** using ambulatory **blood pressure monitoring** have shown that all the ARBs produce smooth antihypertensive actions over a 24-hour period...

6/3,K/40 (Item 4 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB

(c)2003 The Gale Group. All rts. reserv.

10253927 SUPPLIER NUMBER: 20788184 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**MEASURING COMPLIANCE.(with medical treatment)**

Fleming Jr., Harris

Drug Topics, v142, n11, p61(1)

June 1, 1998

ISSN: 0012-6616

LANGUAGE: English

RECORD TYPE: Fulltext

WORD COUNT: 620

LINE COUNT: 00055

... can work with them, and you can use them." Direct methods, used most commonly in **clinical research trials**, consist primarily of pharmacological **tracers** and **blood** and urine analysis. While they provide objective evidence, these methods can be very expensive and...

6/3,K/41 (Item 5 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB

(c)2003 The Gale Group. All rts. reserv.

09823347 SUPPLIER NUMBER: 19937356 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Wyeth-Ayerst Receives U.S. Marketing Clearance For New, Once-Daily**

**Effexor (R) XR**

PR Newswire, p1020NYM140

Oct 20, 1997

LANGUAGE: English

RECORD TYPE: Fulltext

WORD COUNT: 824

LINE COUNT: 00074

... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in **blood pressure** in some patients, so regular **blood -pressure monitoring** is recommended. In **clinical trials** of Effexor XR, the overall incidence of sustained increases in **blood pressure** was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/42 (Item 6 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB

(c)2003 The Gale Group. All rts. reserv.

09757179 SUPPLIER NUMBER: 19798382 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer.**

Rutgeerts, Paul; Rauws, Erik; Wara, Pal; Swain, Paul; Hoos, Anton;

Solleder, Eva; Halttunen, Jorma; Dobrilla, Giorgio; Richter, Gerhard;



Prassler, Roland  
Lancet, v350, n9079, p692(5)  
Sep 6, 1997  
ISSN: 0099-5355      LANGUAGE: English      RECORD TYPE: Fulltext; Abstract  
WORD COUNT: 4260      LINE COUNT: 00356

... with the Declaration of Helsinki. Data were recorded carefully in case-record forms and the **study** was **monitored** according to good **clinical** practice regulations.<sup>33</sup>  
Statistics The **sample** size of 250 people per treatment group was based on an expected recurrent bleeding rate...

**6/3,K/43**      (Item 7 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

07616745      SUPPLIER NUMBER: 15949341      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Clinical trials with **ambulatory** blood **pressure** monitoring : **fewer**  
**patients needed?**  
Staessen, Jan A.; Thijs, Lutgarde; Mancia, Giuseppe; Parati, Gianfranco;  
O'Brien, Eoin T.  
Lancet, v344, n8936, p1552(5)  
Dec 3, 1994  
ISSN: 0099-5355      LANGUAGE: ENGLISH      RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 3153      LINE COUNT: 00253

Clinical trials with **ambulatory** blood **pressure** monitoring : **fewer**  
**patients needed?**

... pressure reduction at a given time (eg, the time of peak plasma concentration) and the **blood** pressure changes at all other times.

It has also been suggested that ambulatory **monitoring** may facilitate the conduct of **clinical** trials by the early identification and exclusion of subjects whose **blood** pressure is raised only in the clinic environment (white coat reactors).[19,26] This feature...

**6/3,K/44**      (Item 8 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

07509433      SUPPLIER NUMBER: 15739728      (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Pharmacological treatment of hypertension. (Hypertension Octet)**  
Swales, J.D.  
Lancet, v344, n8919, p380(6)  
August 6, 1994  
ISSN: 0099-5355      LANGUAGE: ENGLISH      RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 5726      LINE COUNT: 00469

... cardiac function in patients with hypertension. JAMA 1989; 261: 873-77. [24] Mancia G. Ambulatory **blood** pressure **monitoring** : **research** and **clinical** applications. J Hypertens 1990; 8 (suppl 7): s1-13. [25] Alderman MH. **Blood** pressure management: individualised treatment based on absolute risk and the potential for benefit. Ann Intern...

**6/3,K/45**      (Item 9 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

07267830 SUPPLIER NUMBER: 15231319 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.**

Watkins, Paul B.; Zimmerman, Hyman J.; Knapp, Margaret J.; Gracon, Stephen I.; Lewis, Karen W.

JAMA, The Journal of the American Medical Association, v271, n13, p992(7)  
April 6, 1994

ISSN: 0098-7484 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 6434 LINE COUNT: 00522

TEXT:

...seven of the 50 patients enrolled.[5] As a result of these initial observations, subsequent **clinical studies** have required frequent (weekly) **monitoring** of **serum** ALT levels.

**6/3,K/46 (Item 10 from file: 148)**

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

06798843 SUPPLIER NUMBER: 14386838 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Dexamethasone therapy for bacterial meningitis in children. (Swiss Meningitis Study Group)**

Schaad, Urs B.; Lips, Ueli; Gnehm, Hanspeter E.; Blumberg, Avihay; Heinzer, Ivo; Wedgwood, Joanna

Lancet, v342, n8869, p457(5)

August 21, 1993

ISSN: 0099-5355 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 4166 LINE COUNT: 00345

... and at the end of antibiotic therapy.[17,18] Adverse or toxic reactions to the **study** drugs were sought by daily **clinical** observation and laboratory **monitoring** of complete **blood** cell count, electrolytes, creatinine, and liver enzymes in **serum**, glucose in urine, and occult blood in stool, on days 1,2, and 3, and...

**6/3,K/47 (Item 11 from file: 148)**

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

06685537 SUPPLIER NUMBER: 13238305 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**CENTER FOR SPECIAL IMMUNOLOGY CLEARED TO PROVIDE IMMUNE RECONSTITUTION THERAPY TO EXISTING PATIENTS; FDA APPROVES IND FOR LIMITED CLINICAL USE**

PR Newswire, p0826LA013

August 26, 1993

LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 328 LINE COUNT: 00028

... it with the FDA within six weeks. The expanded program will be administered as a **monitored clinical trial**," Dr. Reiter concluded.

CSI's immune reconstitution therapy includes an infusion of peripheral **blood** lymphocytes, which are specific types of white blood cells deficient in patients with AIDS. An...

**6/3,K/48 (Item 12 from file: 148)**

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

06125469 SUPPLIER NUMBER: 12562392 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Long-term cardiac prognosis following noncardiac surgery.**  
Mangano, Dennis T.; Browner, Warren S.; Hollenberg, Milton; Li, Juliet;  
Tateo, Ida M.  
JAMA, The Journal of the American Medical Association, v268, n2, p233(7)  
July 8, 1992  
ISSN: 0098-7484 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 5498 LINE COUNT: 00470

... minute.[3] Perioperatively, blood pressure was recorded from either an arterial line or an automated **blood** pressure cuff that was linked to a microcomputer. Heart rate was recorded from the Holter **monitor**.

#### Clinical Care

**Clinical** decisions were not controlled by **study** protocol. Routine **clinical** intraoperative **monitoring** included threelead ECG, pulse oximetry, and mass spectroscopy. Cardiac medications were continued to the morning...

6/3,K/49 (Item 13 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

06125465 SUPPLIER NUMBER: 12561500 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Monitoring for myocardial ischemia during noncardiac surgery: a technology assessment of transesophageal echocardiography and 12-lead electrocardiography.**  
Eisenberg, Mark J.; London, Martin J.; Leung, Jacqueline M.; Browner, Warren S.; Hollenberg, Milton; Tubau, Julio F.; Tateo, Ida M.; Schiller, Nelson B.; Mangano, Dennis T.  
JAMA, The Journal of the American Medical Association, v268, n2, p210(7)  
July 8, 1992  
ISSN: 0098-7484 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 6914 LINE COUNT: 00594

... continuous three-lead ECG, pulse oximetry, and mass spectroscopy were available to physicians. Intra-arterial **blood** pressure, central venous pressure, and pulmonaryartery pressure were also **monitored** if clinically indicated. **Clinical** decisions were unconstrained by **study** protocol.

#### Intraoperative Monitoring

All **monitoring** data were prospectively collected in a standard manner and were then analyzed after surgery (off...

6/3,K/50 (Item 14 from file: 148)  
DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

05921144 SUPPLIER NUMBER: 12280406 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.**  
Carter, H. Ballentine; Pearson, Jay D.; Metter, E. Jeffrey; Brant, Larry J.; Chan, Daniel W.; Andres, Reubin; Fozard, James L.; Walsh, Patrick C.  
JAMA, The Journal of the American Medical Association, v267, n16, p2215(6)  
April 22, 1992  
ISSN: 0098-7484 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 4556 LINE COUNT: 00365

... case-control study may not be representative of changes that occur

in all men being monitored by PSA levels in clinical practice. In this study, PSA measurements were performed on stored serum samples and not on consecutively collected samples over many years as would be the case in clinical practice where the interassay variation...

6/3,K/51 (Item 15 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

05916935 SUPPLIER NUMBER: 12378268 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Ambulatory Monitoring and Blood Pressure Variability. (book reviews)**  
White, William B.  
JAMA, The Journal of the American Medical Association, v267, n22, p3091(1)  
June 10, 1992  
DOCUMENT TYPE: review ISSN: 0098-7484 LANGUAGE: ENGLISH  
RECORD TYPE: FULLTEXT  
WORD COUNT: 839 LINE COUNT: 00070

... with iiii, paper. \$99, ISBN 1-870026-82-9, London, England, Science Press. 1991.

Ambulatory blood pressure monitoring is a relatively new clinical and research technique that uses invasive and noninvasive blood pressure measurement methods combined with computer technology for data analysis to evaluate the variability of...

6/3,K/52 (Item 16 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

04910707 SUPPLIER NUMBER: 09301926 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**New uses and old for carbamazepine. (includes information on generics and on risk of birth defects)**  
Browne, Thomas R., III; Empting, Larry; Lydiard, R. Bruce; Yerby, Mark S.  
Patient Care, v24, n20, p48(15)  
Dec 15, 1990  
ISSN: 0031-305X LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 6629 LINE COUNT: 00562

... that they are taking the drug). Dosage should be tapered when therapy is stopped.

The monitoring protocol used in many clinical trials of carbamazepine requires a complete blood count, liver function screen, and electrolyte determinations before starting treatment, then at the following intervals...

6/3,K/53 (Item 17 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

04874357 SUPPLIER NUMBER: 09713935 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**FDA clears new heart imaging agent for emergency and routine use. (Cardiolite)**  
PR Newswire, p1227PH004  
Dec 27, 1990  
LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 935 LINE COUNT: 00080

... to determine the efficacy of "Cardiolite" in detecting areas at risk of permanent damage. Worldwide **clinical trials** are under way to **monitor** its use in assessing the effectiveness of **blood** clot-dissolving therapies in coronary artery disease.

"Cardiolite" is available in more than 45 countries...

6/3,K/54 (Item 18 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

03940648 SUPPLIER NUMBER: 07038924 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension.**

White, William B.; Schulman, Peter; McCabe, Ellen J.; Dey, Holley M.  
JAMA, The Journal of the American Medical Association, v261, n6, p873(5)  
Feb 10, 1989

ISSN: 0098-7484 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT  
WORD COUNT: 4012 LINE COUNT: 00345.

... in the Hypertension Unit at the University of Connecticut Health Center, Farmington, who underwent ambulatory **blood pressure monitoring** for **clinical** or pharmacologic **research** purposes. Over a period of four years (1983 through 1987), 720 patients underwent ambulatory **blood** pressure monitoring and 77 of these patients were never previously treated with antihypertensive therapy. Twenty...

6/3,K/55 (Item 19 from file: 148)

DIALOG(R)File 148:Gale Group Trade & Industry DB  
(c)2003 The Gale Group. All rts. reserv.

03642701 SUPPLIER NUMBER: 07028837 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Second National Conference on Alcohol Abuse and Alcoholism to be held in San Diego Oct. 31 - Nov. 2. (NEWS ADVISORY)**

PR Newswire, 1005DC010

Oct 5, 1988

LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT  
WORD COUNT: 338 LINE COUNT: 00031

... conference boasts an expanded agenda: general sessions, five conference tracks, poster sessions, roundtables and an **exhibit** and resource center. The **tracks** are **research**; program administration; **clinical** issues; business and labor; and prevention, education and intervention.

Speakers from HHS will include Bowen...

6/3,K/56 (Item 1 from file: 160)

DIALOG(R)File 160:Gale Group PROMT(R)  
(c) 1999 The Gale Group. All rts. reserv.

02314188

**Clinical Data - Marketing Procedures**

Annual Report 1989 p. 0

... heart have been referred to as "Silent Ischemia" and represent a transient reduced flow of **blood** to the cardiac tissue. With seventeen (17) years of experience in the **clinical** and **research** application of ambulatory ECG **monitoring**, the Company has been successful at developing

technology for detecting transient changes in the ambulatory...

6/3,K/57 (Item 1 from file: 621)  
DIALOG(R)File 621:Gale Group New Prod.Annou.(R)  
(c) 2003 The Gale Group. All rts. reserv.

01150650 Supplier Number: 41751309 (USE FORMAT 7 FOR FULLTEXT)  
**Du Pont Merck today reported that the Food and Drug Administration has cleared for use the first nonsurgical cardiac imaging agent that pinpoints heart attack damage, evaluates perfusion (blood flow) and determines pumping efficiency in a single study.**

News Release, pN/A  
Dec 27, 1990  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 771

... to determine the efficacy of "Cardiolite" in detecting areas at risk of permanent damage. Worldwide **clinical trials** are under way to **monitor** its use in assessing the effectiveness of **blood** clot-dissolving therapies in coronary artery disease.  
  
"Cardiolite" is available in more than 45 countries...

6/3,K/58 (Item 1 from file: 636)  
DIALOG(R)File 636:Gale Group Newsletter DB(TM)  
(c) 2003 The Gale Group. All rts. reserv.

03955676 Supplier Number: 50311218 (USE FORMAT 7 FOR FULLTEXT)  
**And Almost Everything Else ...**  
Genesis Report-Dx, v7, n4, pN/A  
Jan 1, 1998  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 6444

... without having a heavyweight marketing partner will probably be limited.  
**METABOLIC DISORDERS/DIABETES**  
Noninvasive glucose **monitor** from Cygnus performs well in **clinical trials** .  
**Blood glucose monitoring** : Cygnus, Inc (Redwood City, CA) has released favorable results from a series of research clinical...

6/3,K/59 (Item 2 from file: 636)  
DIALOG(R)File 636:Gale Group Newsletter DB(TM)  
(c) 2003 The Gale Group. All rts. reserv.

03766575 Supplier Number: 48153272 (USE FORMAT 7 FOR FULLTEXT)  
**And Also of Note ...**  
Genesis Report-Rx, v7, n1, pN/A  
Dec 1, 1997  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 5896

... and transient: dry mouth, headache, constipation, and insomnia. In some patients, however, Meridia substantially increases **blood** pressure, making regular **monitoring** necessary. In **clinical trials**, the number of patients who discontinued Meridia because of hypertension (0.4% for those on...

6/3,K/60 (Item 3 from file: 636)

DIALOG(R)File 636:Gale Group Newsletter DB(TM)  
(c) 2003 The Gale Group. All rts. reserv.

03045365 Supplier Number: 46218388 (USE FORMAT 7 FOR FULLTEXT)  
**PRESENILIN GENE CONVICTED OF BOTH EARLY ONSET, LATE-ONSET ALZHEIMER'S**  
BIOWORLD Today, v7, n50, pN/A  
March 12, 1996  
Language: English Record Type: Fulltext  
Document Type: Magazine/Journal; Trade  
Word Count: 411

... Alzheimer's-type dementia, and 185 age-matched controls. In a separate cohort they took **blood** from 29 septuagenarian African-American patients of both sexes, plus controls.

All **clinical** centers contributing subjects to the **study** have a **track** record averaging 96-percent accuracy in diagnosing Alzheimer's, confirmed by post-mortem follow-ups...

6/3,K/61 (Item 4 from file: 636)

DIALOG(R)File 636:Gale Group Newsletter DB(TM)  
(c) 2003 The Gale Group. All rts. reserv.

01446057 Supplier Number: 41939750 (USE FORMAT 7 FOR FULLTEXT)  
**COFFEE INTAKE LINKED TO HEART ATTACK RISK IN STUDY**  
Food Chemical News, v33, n3, pN/A  
March 18, 1991  
Language: English Record Type: Fulltext  
Document Type: Newsletter; Trade  
Word Count: 447

... of the poster presentation. The risk was also independent of other factors such as age, **serum** cholesterol in **medical** school, and hypertension, the **researchers** said.

**Tracking** 1,040 former **medical** students, the Johns Hopkins **researchers** found relative coronary heart disease risks associated with five daily cups of coffee as 1...

Set	Items	Description
S1	2496039	TRACK? OR TRACE? OR TRACING OR MONITOR?
S2	381746	(CLINICAL OR MEDICAL) (5N) (STUDIES OR STUDY OR RESEARCH? OR TRIAL?)
S3	4780	S1(5N)S2
S4	229	S3(15N) (SAMPLE? OR EXHIBIT? OR BLOOD? OR SERUM OR GENOTYP? OR PHENOTYP?)
S5	101	S4 NOT PY>1999
S6	85	RD (unique items)

? show files

File 20:Dialog Global Reporter 1997-2003/Apr 25  
(c) 2003 The Dialog Corp.

File 476:Financial Times Fulltext 1982-2003/Apr 25  
(c) 2003 Financial Times Ltd

File 610:Business Wire 1999-2003/Apr 25  
(c) 2003 Business Wire.

File 613:PR Newswire 1999-2003/Apr 25  
(c) 2003 PR Newswire Association Inc

File 624:McGraw-Hill Publications 1985-2003/Apr 24  
(c) 2003 McGraw-Hill Co. Inc

File 634:San Jose Mercury Jun 1985-2003/Apr 24  
(c) 2003 San Jose Mercury News

File 810:Business Wire 1986-1999/Feb 28  
(c) 1999 Business Wire

File 813:PR Newswire 1987-1999/Apr 30  
(c) 1999 PR Newswire Association Inc

File 442:AMA Journals 1982-2003/Aug B3  
(c)2003 Amer Med Assn -FARS/DARS apply

File 149:TGG Health&Wellness DB(SM) 1976-2003/Apr W2  
(c) 2003 The Gale Group

File 444:New England Journal of Med. 1985-2003/Apr W4  
(c) 2003 Mass. Med. Soc.



6/3,K/1 (Item 1 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

08576114 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**New SND Solutions Framework Offers Business-Driven Applications To Extend  
the Functionality of Sales Automation Systems**  
PR NEWSWIRE  
December 06, 1999  
JOURNAL CODE: WPRW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 415

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... Solutions Framework  
SND Solutions Framework delivers a complete platform of application  
modules, including Marketing Budget **Tracking**, **Sample0** Allocation,  
**Clinical Trials** Management, and Literature Ordering, that can be  
enhanced to support client-specific business processes. The...

6/3,K/2 (Item 2 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

07512894 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Micrologix initiates phase II clinical trials of MBI 226**  
CANADA NEWSWIRE  
September 30, 1999  
JOURNAL CODE: WCNW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 666

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... counter)

Micrologix is pleased to announce the commencement of a two-part US  
Phase II **clinical trial** as part of the fast **track** development program  
of MBI 226 for the prevention of central venous catheter-related  
**bloodstream** infection. The trial, developed in consultation with the US  
Food & Drug Administration (FDA), is designed...

6/3,K/3 (Item 3 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

05961799 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Varian, Inc. Signs \$6 Million Sales Agreement With Seiko Instruments Inc.  
'SII'; SII to Resell Analytical Instrument Line in Japan**  
BUSINESS WIRE  
June 29, 1999  
JOURNAL CODE: WBWE LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 455

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... for measuring the concentrations of a wide range of chemical  
elements in a variety of **samples**. Major applications include

environmental monitoring , life science and clinical studies , industrial quality assurance, geo-chemical exploration, and metallurgical analysis.

Varian, Inc.'s Vista system is...

6/3,K/4 (Item 4 from file: 20)

DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

05379111 (USE FORMAT 7 OR 9 FOR FULLTEXT)

**Home Blood Pressure Telemonitoring Service Brings Reliable, Timely Data to Doctors**

PR NEWSWIRE

May 19, 1999

JOURNAL CODE: WPRW LANGUAGE: English RECORD TYPE: FULLTEXT

WORD COUNT: 710

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... of readings, in a patient's normal environment. Dr. Pickering is presenting results of a **clinical trial** of home **blood pressure monitoring** with BPLink at the ASH meeting. Development and clinical testing of the BPLink system has...

6/3,K/5 (Item 5 from file: 20)

DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

05252907 (USE FORMAT 7 OR 9 FOR FULLTEXT)

**Strategic Network Designs Launches Vertical Market Practice to Provide Sales Automation Solutions to the Pharmaceutical Industry**

BUSINESS WIRE

May 10, 1999

JOURNAL CODE: WBWE LANGUAGE: English RECORD TYPE: FULLTEXT

WORD COUNT: 850

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... especially for the pharmaceutical industry. Working from a standard model, SND has developed solutions for **Sample Ordering**, Literature Ordering, **Clinical Trials Management** and Marketing Budget **Tracking** systems. This application model enables SND to provide clients with economies of scale in implementation...

6/3,K/6 (Item 6 from file: 20)

DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

04604093 (USE FORMAT 7 OR 9 FOR FULLTEXT)

**PE Biosystems Introduces System to Rapidly Identify Drug-Resistant HIV Strains**

BUSINESS WIRE

March 11, 1999

JOURNAL CODE: WBWE LANGUAGE: English RECORD TYPE: FULLTEXT

WORD COUNT: 865

... complete, automated system for standardized, sequence-based

genotyping of resistance mutations in HIV. The HIV **Genotyping** System is expected to be of immediate use in investigational **clinical trials** to **monitor** the development of drug-resistant HIV strains and assess the effectiveness of anti-HIV drugs...

**6/3,K/7** (Item 7 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

03167963 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**First Consumer Advertising Campaign for Prescription Weight-Management Product Launched**  
PR NEWSWIRE  
October 20, 1998  
JOURNAL CODE: WPRW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 1448

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... include dry mouth, headache, insomnia and constipation. Some people taking **MERIDIA** experienced substantial increases in **blood** pressure and heart rate. Regular **blood pressure monitoring** is required when prescribing **MERIDIA**. **Clinical studies** showed that these **blood** pressure and heart rate increases generally occur early on in treatment and the prescribing physician...

**6/3,K/8** (Item 8 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

02343974 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Health Canada Approves Treatment For Suppression Of Genital Herpes**  
CANADA NEWSWIRE  
July 28, 1998 9:51  
JOURNAL CODE: WCNW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 889

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... said Dr. Diaz-Mitoma. ``Twice-daily dosing allows the drug to continually circulate in the **bloodstream** so there is a greater potential to stop the virus in its **tracks** ,'' he continued.

**One-Year Clinical Trial**

In a subsequent one-year, multi-centre study, Famvir(R) 250 mg taken twice-daily...

**6/3,K/9** (Item 9 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

02215247 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Studies Show That the Antidepressant Effexor(R) XR Also Provides Effective Relief of Anxiety Symptoms**  
PR NEWSWIRE  
July 15, 1998 9:21  
JOURNAL CODE: WPRW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 747

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in blood pressure in some patients, so regular blood -pressure monitoring is recommended. In clinical trials of Effexor XR, the overall incidence of sustained increases in blood pressure was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/10 (Item 10 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

02187793 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Study Demonstrates That Effexor Saves Costs in Treating Major Depression**  
BUSINESS WIRE  
July 13, 1998 9:26  
JOURNAL CODE: WBWE LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 873

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in blood pressure in some patients, so regular blood -pressure monitoring is recommended. In clinical trials of Effexor XR, the overall incidence of sustained increases in blood pressure was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/11 (Item 11 from file: 20)  
DIALOG(R)File 20:Dialog Global Reporter  
(c) 2003 The Dialog Corp. All rts. reserv.

01809632 (USE FORMAT 7 OR 9 FOR FULLTEXT)  
**Studies Show Effexor(R) XR Produces Significantly Higher Depression Remission Rates Than Prozac**  
PR NEWSWIRE  
June 02, 1998 9:17  
JOURNAL CODE: WPRW LANGUAGE: English RECORD TYPE: FULLTEXT  
WORD COUNT: 659

(USE FORMAT 7 OR 9 FOR FULLTEXT)

... placebo-treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in bloodpressure in some patients, so regular blood -pressure monitoring is recommended. In clinical trials of Effexor XR, the overall incidence of sustained increases in blood pressure was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood pressure...

6/3,K/12 (Item 1 from file: 476)  
DIALOG(R)File 476:Financial Times Fulltext  
(c) 2003 Financial Times Ltd. All rts. reserv.

0008505605 BOGFEEAADYFT  
News: UK: Watchdog attacks NHS training

MARK SUZMAN, Social Affairs Correspondent  
Financial Times, London Edition 1 ED, P 12  
Wednesday, June 5, 1996  
DOCUMENT TYPE: Stories; NEWSPAPER LANGUAGE: ENGLISH RECORD TYPE:  
FULLTEXT  
Word Count: 341

...government to ensure that training for and monitoring of clinical activities is properly implemented and **monitored**. The previous **study** had been criticised by **medical** groups as unrepresentative due to its small **sample** size.

According to Dr Jonathan Boyce, the director of health studies at the commission, the...

6/3,K/13 (Item 1 from file: 634)  
DIALOG(R)File 634:San Jose Mercury  
(c) 2003 San Jose Mercury News. All rts. reserv.

06177047  
**DEVICE COULD SAVE DIABETICS FROM BLOODLETTING**  
San Jose Mercury News (SJ) - Tuesday June 25, 1991  
By: Associated Press  
Edition: Morning Final Section: Science & Medicine Page: 2C  
Word Count: 196

...research director of Futrex Inc. in Gaithersburg, Md.

"If the technology is proven effective in **clinical trials**, **blood** glucose **monitoring** could be pain-free and far more convenient," Rosenthal said.

An estimated 14 million Americans...

6/3,K/14 (Item 2 from file: 634)  
DIALOG(R)File 634:San Jose Mercury  
(c) 2003 San Jose Mercury News. All rts. reserv.

03579159  
**TWO OF A KIND -- RELATIVELY SPEAKING RESEARCH ON TWINS FINDS ASTONISHING**  
**'COINCIDENCES' OF NAMES, BEHAVIOR, JOBS**  
SAN JOSE MERCURY NEWS (SJ) - Thursday, October 2, 1986  
By: PAULA FROKE, Associated Press  
Edition: Stock Final Section: Front Page: 2A  
Word Count: 998

...other studies.'

During their week at the university, the twins are asked to provide complete **medical** histories. **Researchers** **monitor** their hearts, **blood**, **blood** pressure, allergies, and motor skills such as reflexes, hand steadiness and hand-eye coordination.

Other...

6/3,K/15 (Item 1 from file: 810)  
DIALOG(R)File 810:Business Wire

(c) 1999 Business Wire . All rts. reserv.

0658870 BW1488

**OMRON HEALTHCARE 2: World's smallest blood pressure monitor; goes where you go, lets your finger do the "talking"**

January 06, 1997

Byline: Business Editors, Health & Medical Writers

...numbers on the front of the unit.

Created by the market's leading manufacturer of **blood pressure monitors** and based on **clinical research** that has proven a direct relationship between **blood pressure** in the finger and the arm, the product is useful for those who need...

6/3,K/16 (Item 2 from file: 810)

DIALOG(R)File 810:Business Wire

(c) 1999 Business Wire . All rts. reserv.

0412467 BW035

**HEMACARE CORP: HemaCare reports on regulatory status of Immupath -- potential AIDS treatment**

June 16, 1994

Byline: Health/Medical Writers

...mm3. (Decreasing CD4 cell concentrations are indicators of AIDS progression.)

The FDA has approved the **study** 's design, **sample** size, endpoints, **clinical monitoring** and manufacturing plan but has questioned the viral inactivation procedures used in processing Immupath. On....

6/3,K/17 (Item 3 from file: 810)

DIALOG(R)File 810:Business Wire

(c) 1999 Business Wire . All rts. reserv.

0378414 BW045

**THERATECH: TheraTech completes phase III clinical trials of testosterone patch for the treatment of male hormone deficiency**

January 12, 1994

Byline: Medical/Business Editors

...LRS

testosterone patch for periods lasting six to 12 months, and were evaluated by measuring **serum** hormone levels, assessing hypogonadal symptoms and **monitoring** safety parameters.

The **studies** were conducted at **medical** centers in the United States and Sweden, including the Johns Hopkins School of Medicine, the...

6/3,K/18 (Item 4 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0339096 BW729

**CHROMATICS CLR SCI INTL: Investors Associates initiates coverage of Chromatics**

June 10, 1993

Byline: Business Editors

...doctor would merely scan the infant's skin and receive a diagnosis that has, in **clinical research studies**, tracked in direct ratio to **blood** testing. The company, working in conjunction with Mt. Sinai Hospital, began the trials in 1988...

6/3,K/19 (Item 5 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0199934 BW728

**CLINICAL DATA: Clinical Data sells Enviromed subsidiary to Browning Ferris Industries**

October 31, 1990

Byline: Business Editors

...subsidiary, Vital Scientific NV, will continue to manufacture photometric instrumentation used in the analysis of **blood** chemistry. The Drug Research Service Division will continue to provide Ambulatory ECG and **Blood** Pressure **monitoring** services to pharmaceutical companies and **medical research** institutes in the United States and Europe.  
Israel M. Stein, M.D., president of Clinical...

6/3,K/20 (Item 6 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0162583 BW745

**CLINICAL DATA 2: Clinical Data secures stockholder approval and closes divestiture**

February 7, 1990

Byline: Business Editors/Medical Writers

...Data, through its Drug Research Services Division will continue to provide Ambulatory ECG (Holter) and **Blood** Pressure **monitoring** services to pharmaceutical companies and **medical research** institutes. The Drug **Research** Services Division works with 15 international drug companies, performs studies in the United States,

Canada...

6/3,K/21 (Item 7 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0159291 BW713

**CLINICAL DATA: Clinical Data and United Medical sign definitive agreement**

January 16, 1990

Byline: Business Editors

...Drug Research Services Division of Clinical Data will continue to provide Ambulatory ECG (Holter) and **Blood Pressure monitoring** services to pharmaceutical companies and **medical research** institutes in the United States and Europe. Clinical Data will also, through its Dutch subsidiary...

6/3,K/22 (Item 8 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0148314 BW901

**UNITED MEDICAL: United Medical signs letter to acquire Clinical Data Inc.**

October 19, 1989

Byline: Business Editors And Medical Writers

...operation, its research division provides complete data analysis and management services of Holter and ambulatory **blood pressure monitoring studies** for pharmaceutical companies worldwide. United **Medical** Corp.'s other health-care services include physical examinations, electronic new drug applications for submission...

6/3,K/23 (Item 9 from file: 810)  
DIALOG(R)File 810:Business Wire  
(c) 1999 Business Wire . All rts. reserv.

0148300 BW880

**CLINICAL DATA: (UM) Clinical Data's Diagnostic Services Division to be acquired by United Medical**

October 19, 1989

Byline: Business Editors

...the Drug Research Services Division of Clinical Data will continue to provide Ambulatory ECG and **Blood Pressure monitoring** services to pharmaceutical companies and **medical research** institutes in the United States and Europe. Clinical Data will through its Dutch subsidiary, Vital...



6/3,K/24 (Item 1 from file: 813)  
DIALOG(R)File 813:PR Newswire  
(c) 1999 PR Newswire Association Inc. All rts. reserv.

1170689 NYM140  
**Wyeth-Ayerst Receives U.S. Marketing Clearance For New, Once-Daily  
Effexor(R) XR**

DATE: October 20, 1997 15:25 EDT WORD COUNT: 738

...treated patients by the second week of treatment. Venlafaxine is associated with sustained increases in **blood** pressure in some patients, so regular **blood -pressure monitoring** is recommended. In **clinical trials** of Effexor XR, the overall incidence of sustained increases in **blood** pressure was 3%. Less than 1% of patients discontinued Effexor XR due to elevated blood...

6/3,K/25 (Item 2 from file: 813)  
DIALOG(R)File 813:PR Newswire  
(c) 1999 PR Newswire Association Inc. All rts. reserv.

0780508 CL011  
**NORTHFIELD LABORATORIES REPORTS SECOND QUARTER RESULTS**

DATE: January 20, 1995 10:55 EST WORD COUNT: 1,121

...of blood. There was no evidence of fever, no abnormal changes in heart rate or **blood** pressure, no vasoconstriction and no evidence of organ dysfunction in any recipient.

"Phase II **clinical trials** continue to progress on **track**," said Richard DeWoskin, Chairman and CEO. "With the success of our initial Phase II trials..."

6/3,K/26 (Item 3 from file: 813)  
DIALOG(R)File 813:PR Newswire  
(c) 1999 PR Newswire Association Inc. All rts. reserv.

0625930 LA013  
**CENTER FOR SPECIAL IMMUNOLOGY CLEARED TO PROVIDE IMMUNE RECONSTITUTION  
THERAPY TO EXISTING PATIENTS; FDA APPROVES IND FOR LIMITED CLINICAL USE**

DATE: August 26, 1993 09:58 EDT WORD COUNT: 286

...it with the FDA within six weeks. The expanded program will be administered as a **monitored clinical trial**," Dr. Reiter concluded.

CSI's immune reconstitution therapy includes an infusion of peripheral **blood** lymphocytes, which are specific types of white blood cells deficient in patients with AIDS. An...

6/3,K/27 (Item 4 from file: 813)  
DIALOG(R)File 813:PR Newswire  
(c) 1999 PR Newswire Association Inc. All rts. reserv.

0332076

PH004

FDA CLEARS NEW HEART IMAGING AGENT FOR EMERGENCY AND ROUTINE USE

DATE: December 27, 1990

09:29 EST

WORD COUNT: 854

...to determine the efficacy of "Cardiolite" in detecting areas at risk of permanent damage. Worldwide **clinical** trials are under way to **monitor** its use in assessing the effectiveness of **blood** clot-dissolving therapies in coronary artery disease.

"Cardiolite" is available in more than 45 countries...

6/3,K/28 (Item 5 from file: 813)

DIALOG(R)File 813:PR Newswire

(c) 1999 PR Newswire Association Inc. All rts. reserv.

0109942

DC010A

SECOND NATIONAL CONFERENCE ON ALCOHOL ABUSE AND ALCOHOLISM TO BE HELD IN  
SAN DIEGO OCT. 31 - NOV. 2

DATE: October 5, 1988

12:12 E.T.

WORD COUNT: 324

...conference boasts an expanded agenda: general sessions, five conference tracks, poster sessions, roundtables and an **exhibit** and resource center. The **tracks** are **research**; program administration; **clinical** issues; business and labor; and prevention, education and intervention.

Speakers from HHS will include Bowen...

6/3,K/29 (Item 1 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00108858

COPYRIGHT American Medical Association 1998

Clinical Research Designs for Emerging Treatments for Alzheimer Disease  
Moving Beyond Placebo-Controlled Trials (ARTICLE)

KNOPMAN, DAVID; KAHN, JEFFREY; MILES, STEVEN

Archives of Neurology

Nov, 1998; Special: tzn1425

LINE COUNT: 00473

... results.11/ Tacrine therapy requires 4 times a day dosing and either weekly or biweekly **blood** test **monitoring** (for transaminase elevations). In **clinical** **trials**, more than 50% of patients receiving high-dose tacrine stopped taking it before the end...

6/3,K/30 (Item 2 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00106394

COPYRIGHT American Medical Association 1998

**Coronary Artery Disease in Women A Historical Perspective (ARTICLE)**

THOMAS, JOAN L.; BRAUS, PATRICIA A.  
Archives of Internal Medicine  
Feb 23,, 1998; Review Article: tzi333  
LINE COUNT: 00484

... million to establish the Office of Research on Women's Health at the NIH, to **monitor** the inclusion of women in **clinical trials** funded by the agency.6,24/

A second National Heart, Lung, and Blood Institute conference examining women and heart disease took place in 1992.23/ Led by Dr...

6/3,K/31 (Item 3 from file: 442)

DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00094752

COPYRIGHT American Medical Association 1995

**Is Methylphenidate Like Cocaine? Studies on Their Pharmacokinetics and Distribution in the Human Brain (ARTICLE)**

VOLKOW, NORA D.; DING, YU-SHIN; FOWLER, JOANNA S.; WANG, GENE-JACK;  
LOGAN, JEAN; GATLEY, JOHN S.; DEWEY, STEPHEN; ASHBY, CHARLES;  
LIEBERMANN, JEFFREY; HITZEMANN, ROBERT; WOLF, ALFRED P.  
Archives of General Psychiatry  
June, 1995; Original Article: ps\_456  
LINE COUNT: 00676

... throughout the study, and selected plasma samples were analyzed for the presence of unchanged radiotracer. **Blood** sampling was performed in the same manner as that for the human studies. Vitalsigns were **monitored** throughout the length of the **study** (90303B **monitor**, SpaceLabs Medical, Redmond, Wash). Details about the procedures have been published./23/

DATA ANALYSES

Regions of interest...

6/3,K/32 (Item 4 from file: 442)

DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00053995

COPYRIGHT American Medical Association 1992

**Long-term cardiac prognosis following noncardiac surgery.**

Mangano, Dennis T.; Browner, Warren S.; Hollenberg, Milton; Li, Juliet;  
Tateo, Ida M.  
JAMA, The Journal of the American Medical Association  
July 8, 1992; v268: p233(7)  
LINE COUNT: 00481

... minute./3/ Perioperatively, blood pressure was recorded from either an arterial line or an automated **blood** pressure cuff that was linked to a microcomputer. Heart rate was recorded from the Holter **monitor**.

Clinical Care

**Clinical** decisions were not controlled by **study** protocol. Routine

**clinical** intraoperative **monitoring** included threelead ECG, pulse oximetry, and mass spectroscopy. Cardiac medications were continued to the morning...

6/3,K/33 (Item 5 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00053991  
COPYRIGHT American Medical Association 1992

**Monitoring for myocardial ischemia during noncardiac surgery: a technology assessment of transesophageal echocardiography and 12-lead electrocardiography.**

Eisenberg, Mark J.; London, Martin J.; Leung, Jacqueline M.; Browner, Warren S.; Hollenberg, Milton; Tubau, Julio F.; Tateo, Ida M.; Schiller, Nelson B.; Mangano, Dennis T.  
JAMA, The Journal of the American Medical Association  
July 8, 1992; v268: p210(7)  
LINE COUNT: 00605

... continuous three-lead ECG, pulse oximetry, and mass spectroscopy were available to physicians. Intra-arterial **blood** pressure, central venous pressure, and pulmonaryartery pressure were also **monitored** if clinically indicated. **Clinical** decisions were unconstrained by **study** protocol.

**Intraoperative Monitoring**

All **monitoring** data were prospectively collected in a standard manner and were then analyzed after surgery (off...

6/3,K/34 (Item 6 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00053779  
COPYRIGHT American Medical Association 1992

**Ambulatory Monitoring and Blood Pressure Variability.**\_(book reviews) (review)

White, William B.  
JAMA, The Journal of the American Medical Association  
June 10, 1992; v267: p3091(1)  
LINE COUNT: 00074

... with iiii, paper. \$99, ISBN 1-870026-82-9, London, England, Science Press. 1991.

**Ambulatory blood pressure monitoring** is a relatively new **clinical** and **research** technique that uses invasive and noninvasive **blood** pressure measurement methods combined with computer technology for data analysis to evaluate the variability of...

6/3,K/35 (Item 7 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00052696

**The Impact of Long-term Warfarin Therapy on Quality of Life: Evidence From a Randomized Trial (Article)**

Lancaster, Tim R., MRCP; Singer, Daniel E., MD; Sheehan, Mary A., RN; Oertel, Lynn B., RN-C, MS; Maraventano, Sue W., RN; Hughes, Robert A., MD; Kistler, J. Philip, MD  
Archives of Internal Medicine  
1991; 151: 1944 (6)

...of the increased risk of bleeding conferred by warfarin and also because of the frequent **blood** tests and close medical follow-up needed to **monitor** warfarin therapy. Randomized **clinical trials** are providing valid estimates of warfarin's efficacy and risk of hemorrhage. Our work assessed...

6/3,K/36 (Item 8 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00052683

**Growth Hormone Therapy in Hypophosphatemic Rickets (Article)**

Wilson, Darrel M., MD; Lee, Phillip D. K., MD; Morris, Alan H., MD; Reiter, Edward O., MD; Gertner, Joseph M., MB, MCRP; Marcus, Robert, MD; Quarmby, Valerie E., PhD; Rosenfeld, Ron G., MD  
American Journal of Diseases of Children  
1991; 145: 1165 (6)

... of the study. Nutritional intake of calcium, phosphorus, protein, carbohydrate, fat, and total energy was **monitored** by the **Clinical Research** Center dietitian at each institution. Assays Growth hormone levels were determined by immunoassay. **Serum** and urine phosphate and calcium levels, serum alkaline phosphatase levels, and other biochemical measures were...

6/3,K/37 (Item 9 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00043313

Copyright (C) 1988 American Medical Association

**Pepsin Release by Prostaglandin E1 Analogue; A Potential Therapeutic Problem**

BASSON, MARC D.; ZUCKER, KARL A.; ADRIAN, THOMAS E.; ZDON, MICHAEL J.; BALLANTYNE, GARTH H.; MODLIN, IRVIN M.  
Archives of Surgery  
April, 1988; 123: 431-433 1988;  
LINE COUNT: 00158 WORD COUNT: 02190

...might yield better results than prostaglandin therapy alone. It may also be useful in future **clinical trials** of the prostaglandins to **monitor** pepsinogen secretion via **serum** pepsinogen levels or mucosal biopsies. Changes in pepsinogen secretion should be considered in the choice...

6/3,K/38 (Item 10 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00039740  
Copyright (C) 1986 American Medical Association

**Cefoxitin Plus Tobramycin and Clindamycin Plus Tobramycin; A Prospective  
Randomized Comparison in the Therapy of Mixed Aerobic/Anaerobic Infections  
(ORIGINAL ARTICLE)**

NICOLLE, LINDSAY E.; HARDING, GODFREY K. M.; LOUIE, THOMAS J.; THOMSON,  
MARGARET J.; BLANCHARD, ROBERT J.  
Archives of Surgery  
August, 1986; 121: 891-8961986;  
LINE COUNT: 00359 WORD COUNT: 04960

...surgeon and the infectious disease consultant.

Prior to institution of therapy with the study antimicrobial, blood cultures, hematologic and biochemistry studies, and urine specimens were obtained. Patients receiving the study antimicrobial were monitored for clinical response, number of daily bowel movements biochemistry, hematology, urinalysis, and serum tobramycin levles, and repeated cultures when appropriate. Tests were repeated at the termination of the...

6/3,K/39 (Item 11 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00031656  
Copyright (C) 1986 American Medical Association

**Total and Free Serum Concentrations of Carbamazepine and  
Carbamazepine-10,11-Epoxyde in Children With Epilepsy ( ORIGINAL  
CONTRIBUTION)**

AGBATO, OLATOYE A.; ELYAS, ABDULMAJID A.; PATSALOS, PHILIP N.; BRETT,  
EDWARD M.; LASCELLES, PETER T.  
Archives of Neurology  
November, 1986; 43: 1111-11161986;  
LINE COUNT: 00326 WORD COUNT: 04502

**CITED REFERENCES:**

...6. Hoppener RJ, Kuyser A, Meyer JWA, et al: Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects. Epilepsia 1980;21:341-350.

7. Perucca E: Free level monitoring of antiepileptic drugs: Clinical usefulness and case studies. Clin Pharmacokinet 1984;9(suppl 1):7178.

8. Bourgeois BFD, Wad N: Individual and combined...

6/3,K/40 (Item 12 from file: 442)  
DIALOG(R) File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00029991

Copyright (C) 1987 American Medical Association

**Ambulatory Blood Pressure Monitoring in Patients With Panic Disorder (ORIGINAL INVESTIGATIONS)**

WHITE, WILLIAM B.

Archives of Internal Medicine

November, 1987; 147: 1973-1975 1987;

LINE COUNT: 00159 WORD COUNT: 02199

... studies, (Ref. 4) and increases of ten to 35 bpm have been noted using ambulatory **monitoring** equipment in **clinical studies**. (Ref. 5,6) Recently, we described two patients who presented with episodic elevations of the **blood** pressure secondary to panic disorder. (Ref. 7) These cases made us recognize that patients of... not changed or have increased minimally. (Ref. 20,21)

It is apparent from this first **clinical study** of **blood pressure monitoring** in patients with panic disorder that further cardiovascular studies are desirable. Evaluation for the presence...

6/3,K/41 (Item 13 from file: 442)

DIALOG(R) File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00027056

Copyright (C) 1984 American Medical Association

**Tricyclic Antidepressant Therapy for Peptic Ulcer Disease (TODAY'S PRACTICE OF MEDICINE)**

RIES, RICHARD K.; GILBERT, DAVID A.; KATON, WAYNE

Archives of Internal Medicine

March, 1984; 144: 566-569 1984;

LINE COUNT: 00290 WORD COUNT: 04010

... Other advantages of these agents include their long half-lives, low cost, and readily available **serum monitoring**. Further **clinical studies** with detailed physiologic and psychologic observations and **serum monitoring** using TCAs in patients with peptic ulcer disease are needed. (Arch Intern Med 1984...

6/3,K/42 (Item 14 from file: 442)

DIALOG(R) File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00026762

Copyright (C) 1987 American Medical Association

**Imipramine in Prepubertal Major Depressive Disorders (ORIGINAL ARTICLE)**

PUIG-ANTICH, JOAQUIM; PEREL, JAMES M.; LUPATKIN, WILLIAM; CHAMBERS, WILLIAM J.; TABRIZI, MARY ANN; KING, JANET; GOETZ, RAYMOND; DAVIES, MARK; STILLER, RICHARD L.

Archives of General Psychiatry

January, 1987; 44: 81-89 1987;

LINE COUNT: 00606 WORD COUNT: 08376

... of the pills (except the pharmacist) and to plasma levels (except the pharmacology laboratory). The **clinical monitor** and the **research nurse** collected side effect scales, ECGs, and **blood** pressure values. At the end of the imipramine protocol, the **clinical monitor** and the **research nurse** jointly guessed the patient's assignment to drug or placebo. Although they were not...

...QRS width. This eventuality had been anticipated before the start of the protocol. Thus, ECGs, **blood** pressure values, and side effect scales were kept from all clinical personnel except the **clinical monitor** and **research nurse**, who obtained such measurements and used them in monitoring dosage and systematically kept them...

6/3,K/43 (Item 15 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00023312  
Copyright (C) 1989 American Medical Association

**AIDS Antigen Test (FROM THE FOOD AND DRUG ADMINISTRATION)**

NIGHTINGALE, BY STUART L.  
JAMA, The Journal of the American Medical Association  
December 15, 1989; 262: 3254-1989;  
LINE COUNT: 00038 WORD COUNT: 00527

... have been reported are monitoring the presence of HIV-1 antigen in cocultures of peripheral **blood** lymphocytes and, in **clinical research**, **monitoring** treatment of HIV-1-infected individuals with antiviral drugs. The test is not intended as...

6/3,K/44 (Item 16 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00020656  
Copyright (C) 1989 American Medical Association

**Average Daily Blood Pressure, Not Office Blood Pressure, Determines Cardiac Function in Patients With Hypertension (ORIGINAL CONTRIBUTIONS)**

WHITE, WILLIAM B.; SCHULMAN, PETER; MCCABE, ELLEN J.; DEY, HOLLEY M.  
JAMA, The Journal of the American Medical Association  
February 10, 1989; 261: 873-877-1989;  
LINE COUNT: 00265 WORD COUNT: 03667

...in the Hypertension Unit at the University of Connecticut Health Center, Farmington, who underwent ambulatory **blood** pressure **monitoring** for **clinical** or pharmacologic **research** purposes. Over a period of four years (1983 through 1987), 720 patients underwent ambulatory **blood** pressure monitoring and 77 of these patients were never previously treated with antihypertensive therapy. Twenty...

6/3,K/45 (Item 17 from file: 442)  
DIALOG(R)File 442:AMA Journals  
(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.



00020025

Copyright (C) 1988 American Medical Association

**Adverse Events Associated With 24-Hour Ambulatory Sphygmomanometry (LETTERS)**

BURRIS, JAMES F.

JAMA, The Journal of the American Medical Association

November 4, 1988; 260: 2508-2509 1988;

LINE COUNT: 00051 WORD COUNT: 00705

...an ambulatory blood pressure monitoring device (Table).

**Adverse Events Associated With Use of an Ambulatory Blood Pressure Monitoring Device**

(SEE ORIGINAL SOURCE)

Each of these patients underwent ambulatory blood pressure monitoring as part of a clinical trial of an investigational antihypertensive drug. The devices had been tested, applied, and activated by clinical...

6/3,K/46 (Item 18 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00016665

Copyright (C) 1987 American Medical Association

**Phenylpropanolamine in Patients With Autonomic Impairment (LETTERS )**

KROENKE, MAJ KURT

JAMA, The Journal of the American Medical Association

December 4, 1987; 258: 3121-3122 1987;

LINE COUNT: 00101 WORD COUNT: 01405

... the "Methods" section, one can picture the 14 study patients with autonomic dysfunction, hooked to monitors in a clinical research center, nervously swallowing pills they are told might raise their blood pressure. Indeed, the principles of informed consent would compel the investigators to disclose even more...

6/3,K/47 (Item 19 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00014377

Copyright (C) 1987 American Medical Association

**Nutritional Therapy for High Blood Pressure; Final Report of a Four-Year Randomized Controlled Trial -- The Hypertension Control Program (ORIGINAL CONTRIBUTIONS)**

STAMLER, ROSE; STAMLER, JEREMIAH; GRIMM, RICHARD; GOSCH, FLORA C.; ELMER, PATRICIA; DYER, ALAN; BERMAN, REUBEN; FISHMAN, JOAN; VAN HEEL, NANCY;

CIVINELLI, JEAN; MCDONALD, ARLINE

JAMA, The Journal of the American Medical Association

March 20, 1987; 257: 1484-1491 1987;

LINE COUNT: 00488

WORD COUNT: 06742

... blood pressure and levels of biochemical variables affected by the drugs. Length of observation and sample size did not permit utilizing clinical morbidity and mortality as trial end points, although these were monitored .

**Sample Size**

Sample size was calculated to demonstrate (with alpha 0.05 and beta 0.10) the following...

6/3,K/48 (Item 20 from file: 442)

DIALOG(R)File 442:AMA Journals

(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00005379

Copyright (C) 1984 American Medical Association

**The Lipid Research Clinics Coronary Primary Prevention Trial Results; I. Reduction in Incidence of Coronary Heart Disease (ORIGINAL CONTRIBUTIONS )**

PROGRAM, LIPID RESEARCH CLINICS

JAMA, The Journal of the American Medical Association

January 20, 1984; 251: 351-3641984;

LINE COUNT: 00809 WORD COUNT: 11169

... Little or no differences were seen between the two treatment groups for most of the clinical chemical tests monitored during the study (Appendix C). During the first year, serum alkaline phosphatase levels, iron binding capacity, SGOT levels, and the WBC count were higher in...

6/3,K/49 (Item 1 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01923880 SUPPLIER NUMBER: 63815799 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Linking Community-Based Blood Pressure Measurement to Clinical Care: A Randomized Controlled Trial of Outreach and Tracking by Community Health Workers.**

Krieger, James; Collier, Cheza; Song, Lin; Martin, Donald  
The American Journal of Public Health, 89, 6, 856

June,  
1999

PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0090-0036

LANGUAGE: English RECORD TYPE: Abstract TARGET AUDIENCE: Academic

**Linking Community-Based Blood Pressure Measurement to Clinical Care: A Randomized Controlled Trial of Outreach and Tracking by Community Health Workers.**

6/3,K/50 (Item 2 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01876525 SUPPLIER NUMBER: 57943233 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**There's no place like home: distance technologies of patient monitoring. (The Impact of New Technologies in Medicine)**

British Medical Journal, 319, 7220, 1309  
Nov 13,  
1999

PUBLICATION FORMAT: Magazine/Journal ISSN: 0959-8146 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 269 LINE COUNT: 00028

... meaningful communication and decision support systems are also  
needed for patients and clinicians. Several randomised **clinical trials**  
of computerised home glucose **monitoring** found improved outcomes in  
diabetes care. Trials of home monitoring of **blood** pressure show enhanced  
efficiency. Failure to improve outcomes through home monitoring of  
high-risk pregnancies...

6/3,K/51 (Item 3 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01856471 SUPPLIER NUMBER: 55807393 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Colour doppler imaging for diagnosis of intracranial**

**hypotension. (Statistical Data Included)**

Chao-Ching, Chen; Cheau-Lin, Luo; Shuu-Jiun, Wang; Chang-Ming, Chern;  
Jong-Ling, Fuh; Sheng-Han, Lin; Han-Hwa, Hu  
The Lancet, 354, 9181, 826  
Sept 4,  
1999

DOCUMENT TYPE: Statistical Data Included PUBLICATION FORMAT:  
Magazine/Journal; Refereed ISSN: 0099-5355 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 3323 LINE COUNT: 00314

... Moreover, since changes in the blood flow in the superior  
ophthalmic vein were reversible after **blood** -patch treatment, CDFI would  
also be useful in **monitoring** the therapeutic effect of **clinical**  
management. However, this preliminary **study** included only a small number  
of participants, so further investigations in a larger population are...

6/3,K/52 (Item 4 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01813155 SUPPLIER NUMBER: 53520315 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**What's new in hypertension: update on angiotensin II receptor**

**blockers. (includes related article on the role of angiotensin II in the  
development of hypertension)**

Black, Henry R.  
Consultant, 38, 11, 2715(7)  
Nov,  
1998

PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0010-7069  
LANGUAGE: English RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE:  
Professional  
WORD COUNT: 3491 LINE COUNT: 00308

... receptor in vitro than losartan is, but it is unclear whether this  
feature has any **clinical** implications.(15)  
EFFICACY

**Clinical studies** using ambulatory **blood** pressure **monitoring**

have shown that all the ARBs produce smooth antihypertensive actions over a 24-hour period...

6/3,K/53 (Item 5 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01739991 SUPPLIER NUMBER: 20062550 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Update on rifampin drug interactions. (part 3)**  
Strayhorn, Valerie A.; Baciewicz, Anne M.; Self, Timothy H.  
Archives of Internal Medicine, v157, n21, p2453(6)  
Nov 24,  
1997  
PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0003-9926  
LANGUAGE: English RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE:  
Professional  
WORD COUNT: 4671 LINE COUNT: 00489

... clinical response;  
blocking agents increased propranolol or metoprolol  
dose may be needed  
Chloramphenicol((dagger)) Monitor **serum** chloramphenicol  
concentrations: may need to increase  
dosage  
Dapsone **Monitor clinical** response: additional  
**study** needed when used for  
Pneumocystis carinii prophylaxis;  
monitor for hematologic toxic effects  
Diazepam((dagger)) Monitor...

6/3,K/54 (Item 6 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01730722 SUPPLIER NUMBER: 19987821 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Stress management and exercise training in cardiac patients with myocardial  
ischemia: effects on prognosis and evaluation of mechanisms.**  
Blumenthal, James A.; Jiang, Wei; Babyak, Michael A.; Krantz, David S.;  
Frid, David J.; Coleman, R. Edward; Waugh, Robert; Hanson, Michael;  
Appelbaum, Mark; O'Connor, Christopher; Morris, James J.  
Archives of Internal Medicine, v157, n19, p2213(11)  
Oct 27,  
1997  
PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0003-9926  
LANGUAGE: English RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE:  
Professional  
WORD COUNT: 8022 LINE COUNT: 00699

... participation. Of the 136 patients initially enrolled in the study,  
107 met the criteria of **exhibiting** myocardial ischemia with either mental  
stress testing or ambulatory **monitoring** and were included in the  
**clinical trial**. All subjects received their group assignments  
immediately following the completion of the pretreatment evaluation. Those  
...

6/3,K/55 (Item 7 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01720306 SUPPLIER NUMBER: 19802771 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**The history of multiple sclerosis. (part 2)**

Rolak, Loren A.

Inside MS, v14, n3, p14(2)

Fall,

1996

PUBLICATION FORMAT: Newsletter ISSN: 0739-9774 LANGUAGE: English

RECORD TYPE: Fulltext TARGET AUDIENCE: Consumer

WORD COUNT: 986 LINE COUNT: 00087

... treated people with MS in the 1950s continued to suspect the cause lay in impaired **blood** flow -- so circulation stimulators dominated treatment. These therapies were used without controlled **studies** to **track** the results, called **clinical trials**, so no reproducible or valid information could emerge about their effectiveness.

Breakthroughs expand knowledge but...

**6/3,K/56 (Item 8 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01717679 SUPPLIER NUMBER: 19798382 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer.**

Rutgeerts, Paul; Rauws, Erik; Wara, Pal; Swain, Paul; Hoos, Anton;

Solleder, Eva; Halttunen, Jorma; Dobrilla, Giorgio; Richter, Gerhard;

Prassler, Roland

The Lancet, v350, n9079, p692(5)

Sep 6,

1997

PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0099-5355

LANGUAGE: English RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE:

Professional

WORD COUNT: 4090 LINE COUNT: 00356

... with the Declaration of Helsinki. Data were recorded carefully in case-record forms and the **study** was **monitored** according to good **clinical** practice regulations.<sup>33</sup>

Statistics The **sample** size of 250 people per treatment group was based on an expected recurrent bleeding rate...

**6/3,K/57 (Item 9 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01689291 SUPPLIER NUMBER: 19367523 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**New drug for type II: troglitazone increases insulin sensitivity.**

**(Rezulin) (includes related information)**

McCarren, Marie

Diabetes Forecast, v50, n5, p26(4)

May,

1997

PUBLICATION FORMAT: Magazine/Journal ISSN: 0095-8301 LANGUAGE: English

RECORD TYPE: Fulltext TARGET AUDIENCE: Consumer

WORD COUNT: 1777 LINE COUNT: 00139

... at the University of Chicago, has had about 20 patients on troglitazone as part of **clinical studies**. He recommends that people **monitor** their **blood glucose** levels three or four times a day and keep in close contact with their...

6/3,K/58 (Item 10 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01675093 SUPPLIER NUMBER: 19156192 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Hyperventilation and head injury: controversies and concerns.**

Geraci, Eunell B.; Geraci, Thomas A.

Journal of Neuroscience Nursing, v28, n6, p381(7)

Dec,

1996

PUBLICATION FORMAT: Magazine/Journal ISSN: 0888-0395 LANGUAGE: English

RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional

WORD COUNT: 5183 LINE COUNT: 00453

...ABSTRACT: standard treatment for serious head injuries for over 20 years. Recent technological advances in patient **monitoring** and related **medical research** suggest that unmonitored hyperventilation can lead to secondary brain injury, such as ischemia, by reducing **blood** flow during the prehospital and early emergency phases of treatment, making its continued usage controversial...

6/3,K/59 (Item 11 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01669810 SUPPLIER NUMBER: 19016982 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Oat bran concentrate bread products improve long-term control of diabetes: a pilot study.**

Pick, Mary E.; Hawrysh, Zenia J.; Gee, Margaret I.; Toth, Ellen; Garg, Manohar L.; Hardin, Robert T.

Journal of the American Dietetic Association, v96, n12, p1254(8)

Dec,

1996

PUBLICATION FORMAT: Magazine/Journal ISSN: 0002-8223 LANGUAGE: English

RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional

WORD COUNT: 6187 LINE COUNT: 00534

... products as bread exchanges. Daily energy intake was individualized for weight maintenance.

Dietary intakes were **monitored** by a **research** dietitian; a physician provided **medical** management. Patients were seen every 3 weeks to make anthropometric and dietary assessments, to discuss...

6/3,K/60 (Item 12 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01653801 SUPPLIER NUMBER: 17847456 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Nutrition intervention program of the Modification of Diet in Renal Disease**

**Study: a self-management approach. (includes related article)**

Gillis, Bonnie P.; Caggiula, Arlene W.; Chiavacci, Anne T.; Coyne, Terry; Doroshenko, Linda; Milas, N. Carole; Nowalk, Mary Patricia; Scherch, Laura

Kinzel  
Journal of the American Dietetic Association, v95, n11, p1288(7)  
Nov,  
1995  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0002-8223 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 5679 LINE COUNT: 00489

... and guidelines for vegetarian meal planning. A few participants were given several days of actual **sample** meals or were admitted to a **clinical research** center where food intake was **monitored** closely; these activities provided insights for the interpretation and improvement of estimations of protein intake...

6/3,K/61 (Item 13 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01619849 SUPPLIER NUMBER: 18319731 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Forecasting Alzheimer's disease: brain scans and writing samples may predict dementia. (Cover Story)**  
Fackelmann, Kathleen  
Science News, v149, n20, p312(2)  
May 18,  
1996  
DOCUMENT TYPE: Cover Story PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8423 LANGUAGE: English RECORD TYPE: Fulltext; Abstract  
TARGET AUDIENCE: Academic; Consumer  
WORD COUNT: 2136 LINE COUNT: 00165

... s disease," he says.  
First, however, scientists must determine whether the combination of PET and **blood** tests really does forecast dementia, comments Mony J. de Leon, an Alzheimer's **researcher** at New York University **Medical** Center. To do this, **researchers** must continue **monitoring** their volunteers to see whether they actually develop Alzheimer's, he adds.  
This widespread scientific...

6/3,K/62 (Item 14 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01607279 SUPPLIER NUMBER: 17737854 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Reach new sales heights: dealers share their merchandising tips for blood pressure monitors.**  
Nones, Rachelle  
Independent Living Provider, v10, n7, p60(2)  
Nov-Dec,  
1995  
PUBLICATION FORMAT: Magazine/Journal LANGUAGE: English RECORD TYPE: Fulltext TARGET AUDIENCE: Consumer  
WORD COUNT: 982 LINE COUNT: 00080

... In the mid-1980s, Kaiser Permanente Medical Care Program in San Francisco conducted a home **blood pressure monitoring clinical study** of 467 patients. Results showed that subjects who took their pressures at home made 1...

6/3,K/63 (Item 15 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01606466 SUPPLIER NUMBER: 17467906 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Antithrombotic therapy in children. (includes related article) (Fourth Annual American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, April 1995, Tucson, Arizona)**  
Michelson, Alan D.; Bovill, Edward; Andrew, Maureen  
Chest, v108, n4, p506S(17)  
Oct,  
1995  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0012-3692 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 13382 LINE COUNT: 01211

... solutions for optimizing therapy with oral anticoagulants in children include pediatric anticoagulation clinics,[1] whole blood PT/INR monitors used at home,[2] and clinical trials to determine if lower, safer INR ranges are as efficacious.  
Adverse Effects of Oral Anticoagulants...

6/3,K/64 (Item 16 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01496911 SUPPLIER NUMBER: 15949341 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Clinical trials with ambulatory blood pressure monitoring : fewer patients needed?**  
Staessen, Jan A.; Thijs, Lutgarde; Mancia, Giuseppe; Parati, Gianfranco;  
O'Brien, Eoin T.  
The Lancet, v344, n8936, p1552(5)  
Dec 3,  
1994  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 3093 LINE COUNT: 00253

Clinical trials with ambulatory blood pressure monitoring : fewer patients needed?  
... pressure reduction at a given time (eg, the time of peak plasma concentration) and the blood pressure changes at all other times.  
It has also been suggested that ambulatory monitoring may facilitate the conduct of clinical trials by the early identification and exclusion of subjects whose blood pressure is raised only in the clinic environment (white coat reactors).[19,26] This feature...

6/3,K/65 (Item 17 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01495895 SUPPLIER NUMBER: 15928000 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Long-term xanthine therapy of asthma: enprofylline and theophylline compared.**  
Chapman, Kenneth R.; Ljungholm, Karin; Kallen, Anders  
Chest, v106, n5, p1407(7)  
Nov,



1994

PUBLICATION FORMAT: Magazine/Journal ISSN: 0012-3692 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 4765 LINE COUNT: 00412

... level stability in long-term therapy would call into question the need for routine, frequent **blood level monitoring**. Such a hypothesis deserves further **clinical study**.

Recent publications have suggested that long-term bronchodilator administration to patients with asthma may lead...

**6/3,K/66 (Item 18 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01487733 SUPPLIER NUMBER: 15739728 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Pharmacological treatment of hypertension. (Hypertension Octet)**

Swales, J.D.

The Lancet, v344, n8919, p380(6)

August 6,

1994

PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English

RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional

WORD COUNT: 5619 LINE COUNT: 00469

... function in patients with hypertension. JAMA 1989; 261: 873-77.

[24] Mancina G. Ambulatory blood **pressure** monitoring: **research and clinical applications**. J Hypertens 1990; 8 (suppl 7): s1-13. [25]

Alderman MH. Blood **pressure** management: individualised treatment based on absolute risk and the potential for benefit. Ann Intern Med...

**6/3,K/67 (Item 19 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01483989 SUPPLIER NUMBER: 15596744 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Status of Immupath reported as potential AIDS treatment.**

AIDS Weekly, p8(2)

July 18,

1994

DOCUMENT TYPE: evaluation PUBLICATION FORMAT: Newsletter ISSN:

1069-1456 LANGUAGE: English RECORD TYPE: Fulltext TARGET AUDIENCE:

Professional

WORD COUNT: 425 LINE COUNT: 00042

... 3). (Decreasing CD4 cell concentrations are indicators of AIDS progression.)

The FDA has approved the **study**'s design, **sample** size, endpoints, **clinical monitoring** and manufacturing plan but has questioned the viral inactivation procedures used in processing Immupath. On...

**6/3,K/68 (Item 20 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01483303 SUPPLIER NUMBER: 15505098 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Problems in clinical trials go far beyond misconduct. (includes glossary**

and related articles on effects of ignorance and on meta-analysis and megatrials) (Special News Report: A Close Look at Clinical Trials)

Nowak, Rachel  
Science, v264, n5165, p1538(4)  
June 10,  
1994

PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Academic  
WORD COUNT: 4314 LINE COUNT: 00355

... for death. As a result, many clinical trials look for effects on CD4 counts and **serum** cholesterol levels rather than **monitoring** hard **clinical** endpoints. Most experts in **clinical trials** agree that it's fine to use surrogate markers to identify promising new agents in...

6/3,K/69 (Item 21 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01482795 SUPPLIER NUMBER: 15518780 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**HemaCare reports on regulatory status of Immupath.**  
AIDS Weekly, p14(1)  
June 27,  
1994  
PUBLICATION FORMAT: Newsletter ISSN: 1069-1456 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 429 LINE COUNT: 00042

... lymphocyte concentrations of 50-200/cells per [mm.sup.3].  
The FDA has approved the **study**'s design, **sample** size, endpoints, **clinical monitoring** and manufacturing plan but has questioned the viral inactivation procedures used in processing Immupath. On...

6/3,K/70 (Item 22 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01479406 SUPPLIER NUMBER: 15231319 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.**  
Watkins, Paul B.; Zimmerman, Hyman J.; Knapp, Margaret J.; Gracon, Stephen I.; Lewis, Karen W.  
JAMA, The Journal of the American Medical Association, v271, n13, p992(7)  
April 6,  
1994  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0098-7484 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 6346 LINE COUNT: 00522

TEXT:  
...seven of the 50 patients enrolled.[5] As a result of these initial observations, subsequent **clinical studies** have required frequent (weekly) **monitoring** of **serum** ALT levels.

6/3,K/71 (Item 23 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01435184 SUPPLIER NUMBER: 15024488 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
1993 guidelines for the management of mild hypertension: memorandum from a  
WHO/ISH meeting. (World Health Organization, International Society of  
Hypertension)  
Bulletin of the World Health Organization, v71, n5, p503(15)  
Sept-Oct,  
1993  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0042-9686 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 10532 LINE COUNT: 00908

... a follow-up. Clin. exper. hypertens., A14: 45-53 (1992). [12]  
Mancia, G. Ambulatory blood **pressure** monitoring: **research** and  
clinical **applications**. J. hypertens., 8 (suppl. 7): S1-S13 (1990). [13]  
O'Brien, E. et al. The...

6/3,K/72 (Item 24 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01434803 SUPPLIER NUMBER: 14742164 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Summary of 1993 World Health Organisation-International Society of  
Hypertension guidelines for the management of mild hypertension.  
British Medical Journal, v307, n6918, p1541(6)  
Dec 11,  
1993  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0959-8146 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 4509 LINE COUNT: 00453

... a follow-up. Clin Exp Hypertens [A] 1992;A14:45-53.  
[12] Mancia G. Ambulatory **blood** pressure monitoring : **research**  
and **clinical** applications. J Hypertens 1990;8(suppl 7):S1-S13.  
[13] Zanchetti A. What **blood** pressure level should be treated? In:  
Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and  
...

6/3,K/73 (Item 25 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01434178 SUPPLIER NUMBER: 14386838 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
Dexamethasone therapy for bacterial meningitis in children. (Swiss  
Meningitis Study Group)  
Schaad, Urs B.; Lips, Ueli; Gnehm, Hanspeter E.; Blumberg, Avihay; Heinzer,  
Ivo; Wedgwood, Joanna  
The Lancet, v342, n8869, p457(5)  
August 21,  
1993  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0099-5355 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 4116 LINE COUNT: 00345

... and at the end of antibiotic therapy.[17,18] Adverse or toxic  
reactions to the **study** drugs were sought by daily **clinical** observation  
and laboratory **monitoring** of complete **blood** cell count, electrolytes,  
creatinine, and liver enzymes in **serum**, glucose in urine, and occult

blood in stool, on days 1,2, and 3, and...

6/3,K/74 (Item 26 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01425803 SUPPLIER NUMBER: 13269131 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**IND granted for immune reconstitution therapy. (Investigational New Drug application by Health Professionals Inc.'s Center for Special Immunology) (U.S. Food and Drug Administration)**  
AIDS Weekly, v36, n34, p6(1)  
Sept 6,  
1993  
PUBLICATION FORMAT: Newsletter ISSN: 1069-1456 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 199 LINE COUNT: 00018

... it with the FDA within six weeks. The expanded program will be administered as a **monitored clinical trial**," Reiter concluded.  
CSI's immune reconstitution therapy includes an infusion of peripheral **blood lymphocytes**, which are specific types of white blood cells deficient in patients with AIDS. An...

6/3,K/75 (Item 27 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01366848 SUPPLIER NUMBER: 12280406 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.**  
Carter, H. Ballentine; Pearson, Jay D.; Metter, E. Jeffrey; Brant, Larry J.; Chan, Daniel W.; Andres, Reubin; Fozard, James L.; Walsh, Patrick C.  
JAMA, The Journal of the American Medical Association, v267, n16, p2215(6)  
April 22,  
1992  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0098-7484 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 4402 LINE COUNT: 00365

... case-control study may not be representative of changes that occur in all men being **monitored** by PSA levels in **clinical practice**. In this **study**, PSA measurements were performed on stored **serum samples** and not on consecutively collected **samples** over many years as would be the case in clinical practice where the interassay variation...

6/3,K/76 (Item 28 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01351688 SUPPLIER NUMBER: 11951693 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Measurement of isometric force in children with and without Duchenne's muscular dystrophy.**  
Brussock, Christine M.; Haley, Stephen M.; Munsat, Theodore L.; Bernhardt, Donna B.  
Physical Therapy, v72, n2, p105(10)  
Feb,  
1992

PUBLICATION FORMAT: Magazine/Journal ISSN: 0031-9023 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 4225 LINE COUNT: 00475

... markers that accurately describe disease progression in individuals with DMD have been reported. Levels of **serum** creatine phosphokinase and 3-methylhistidine have been **monitored** in **clinical trials**, but they have been ineffective in judging therapeutic responses to new interventions. [3,4]

The...

6/3,K/77 (Item 29 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01314060 SUPPLIER NUMBER: 11986669 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**'White coat' hypertension in children.**

Hornsby, J. Larry; Mongan, Patrick F.; Taylor, A. Thomas; Treiber, Frank A.  
Journal of Family Practice, v33, n6, p617(7)  
Dec,  
1991

PUBLICATION FORMAT: Magazine/Journal ISSN: 0094-3509 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 3463 LINE COUNT: 00342

... 24-hour blood pressure readings in the normal range) also limits accurate diagnosis when evaluating **blood** pressure in the **medical** setting. [3] **Research** with ambulatory **blood** pressure **monitoring** (ABPM) clearly demonstrates the importance of white coat hypertension in making an accurate diagnosis of...dimensions of "office hypertension." Behav Res Ther 1985; 23:609-12.

[8] Mancina G. Ambulatory **blood** pressure **monitoring** in hypertension **research** and **clinical** practice. ISH Hypertension Yearbook 1986; 93-115.

[9] Waeber B, Scherrer U, Petriolo A, et...

6/3,K/78 (Item 30 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01301693 SUPPLIER NUMBER: 10975717 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Ambulatory blood pressure monitoring in hypertension.**

Hornsby, J. Larry; Mongan, Patrick F.; Taylor, A. Thomas  
American Family Physician, v43, n5, p1631(8)  
May,  
1991

PUBLICATION FORMAT: Magazine/Journal ISSN: 0002-838X LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 2750 LINE COUNT: 00291

... to the development of ABPM monitors that provide an accurate and reliable method for assessing **blood** pressure for **clinical** as well as **research** purposes.(26-28)

#### MEASUREMENT INTERVALS

**Monitors** may be programmed to **sample** **blood** pressure at various intervals, usually every five to 60 minutes for 24 to 48 hours...

6/3,K/79 (Item 31 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01293059 SUPPLIER NUMBER: 10346599 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Management of mild hypertension: selecting an antihypertensive regime.**  
Perez-Stable, Eliseo J.  
The Western Journal of Medicine, v154, n1, p78(10)  
Jan,  
1991  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0093-0415 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional  
WORD COUNT: 8895 LINE COUNT: 00886

... goal at a lower cost. In selected patients with medication side effects, difficult-to-control **blood** pressure, or other undefined circumstances, however, **monitoring** may provide important information.  
**Clinical Trials** for Mild Hypertension--Lessons  
Lessons and Questions  
Including the landmark Veterans Administration (VA) Cooperative Study  
...

6/3,K/80 (Item 32 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01254386 SUPPLIER NUMBER: 09301926 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**New uses and old for carbamazepine. (includes information on generics and on risk of birth defects)**  
Browne, Thomas R., III; Empting, Larry; Lydiard, R. Bruce; Yerby, Mark S.  
Patient Care, v24, n20, p48(15)  
Dec 15,  
1990  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0031-305X LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 6292 LINE COUNT: 00562

... that they are taking the drug). Dosage should be tapered when therapy is stopped.  
The **monitoring** protocol used in many **clinical trials** of carbamazepine requires a complete **blood** count, liver function screen, and electrolyte determinations before starting treatment, then at the following intervals...

6/3,K/81 (Item 33 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01206445 SUPPLIER NUMBER: 09265886  
**National high blood pressure education program working group report on ambulatory blood pressure monitoring.**  
Archives of Internal Medicine, v150, n11, p2265(11)  
Nov,  
1990  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0003-9926 LANGUAGE: English  
RECORD TYPE: Abstract TARGET AUDIENCE: Professional

...ABSTRACT: those at higher risk of heart attack is being studied. It has

proved useful in **research** and **clinical** situations, such as **monitoring** the effects of drugs taken to lower high **blood** pressure, especially since **blood** pressure taken in the doctor's office may be affected by the timing of when...

6/3,K/82 (Item 34 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2003 The Gale Group. All rts. reserv.

01147692 SUPPLIER NUMBER: 06526683 (USE FORMAT 7 OR 9 FOR FULL TEXT)  
**Brain imaging: applications in psychiatry.**  
Andreasen, Nancy C.  
Science, v239, n4846, p1381(8)  
March 18,  
1988  
PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Academic  
WORD COUNT: 6846 LINE COUNT: 00712

... image construction.

Several 123I-labeled tracers, such as 123-I-IMP, are now available for **clinical** imaging **trials** in the United States. These **tracers** are ideal for labeling **blood** flow and may permit examination of perfusion in subcortical regions such as the basal ganglia...

6/3,K/83 (Item 1 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.  
(c) 2003 Mass. Med. Soc. All rts. reserv.

00119463  
Copyright 1999 by the Massachusetts Medical Society

**Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy (Original Articles)**

Kern, Winfried V.; Cometta, Alain; de Bock, Robrecht; Langenaeken, John; Paesmans, Marianne; Gaya, Harold; Zanetti, Giorgio; Calandra, Thierry; Glauser, Michel P.; Crokaert, Francoise; Klastersky, Jean; Skoutelis, Athanasios; Bassaris, Harry; Zinner, Stephen H.; Viscoli, Claudio; Engelhard, Dan; Padmos, Andrew; for the International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.  
The New England Journal of Medicine  
Jul 29, 1999; 341 (5),pp 312-318  
LINE COUNT: 00409 WORD COUNT: 05645

#### CITED REFERENCES

- ...patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
- 28. Makuch R, Simon R. **Sample** size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-40.
- 29. **Monitoring** trial progress. In: Pocock SJ. **Clinical trials** : a practical approach. Chichester, England: John Wiley, 1983:142-59.
- 30. O'Brien PC, Fleming...

6/3,K/84 (Item 2 from file: 444)  
DIALOG(R)File 444:New England Journal of Med.

(c) 2003 Mass. Med. Soc. All rts. reserv.

00102824

Copyright 1987 by the Massachusetts Medical Society

**Therapeutic Efficacy Of Oral Charcoal In Congenital Erythropoietic  
Porphyria (Medical Intelligence)**

Pimstone, Neville R.; Gandhi, Shobha N., M.B.B.S.; Mukerji, Sudhir K.,  
Ph.D.

The New England Journal of Medicine

February 12, 1987; 316 (7), pp 390-393

LINE COUNT: 00376

WORD COUNT: 05193

**TEXT**

...in consecutive clinical studies conducted two weeks apart. In both investigations, skin, urine, and plasma **samples** were obtained, and their porphyrin contents were **monitored**. In the first **clinical study**, the patient ingested the activated charcoal as a slurry (30 g every 3 hours for...

**6/3,K/85 (Item 3 from file: 444)**

DIALOG(R) File 444:New England Journal of Med.

(c) 2003 Mass. Med. Soc. All rts. reserv.

00100454

Copyright 1985 by the Massachusetts Medical Society

**Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with  
Thalassemia Major (Original Article)**

Wolfe, Lawrence; Olivieri, Nancy; Sallan, Darlene, R.N.; Colan, Steven  
; Rose, Vera; Propper, Richard; Freedman, Melvin H.; Nathan, David G.

The New England Journal of Medicine

June 20, 1985; 312 (25), pp 1600-1603

LINE COUNT: 00278

WORD COUNT: 03849

**TEXT**

...All patients had previously undergone splenectomy. None had cardiac disease at the onset of the **study**, as judged by **clinical** examination, echocardiography, and Holter **monitoring**. On entrance into this study, patients began a program of supertransfusion (maintenance of **blood** hemoglobin levels no lower than 12 g per deciliter) and deferoxamine, 25 to 50 mg...



Set	Items	Description
S1	2223801	TRACK? OR TRACE? OR TRACING OR MONITOR?
S2	2451256	(CLINICAL? OR MEDICAL) (5N) (STUDIES OR STUDY OR RESEARCH? OR TRIAL?)
S3	10360541	SAMPLE? OR EXHIBIT? OR BLOOD? OR SERUM OR GENOTYP? OR PHEN-OTYP?
S4	372354	SCIENTIST? OR RESEARCHER? OR WORKER OR ATTENDANT?
S5	13851	S1(5N)S2
S6	2947	S5(15N)S3
S7	9	S6(15N)S4
S8	292	S6(5N) (PROTOCOL? OR STEP? ? OR PROCEDUR?)
S9	222	S8 NOT PY>1999
S10	208	RD (unique items)
S11	237468	CHECKLIST? OR (WORK OR CHECK) ( )LIST? ? OR ROSTER? ? OR ASSIGNMENT? OR WORKLIST?
S12	0	S10(20N)S11
S13	1	S10 AND S11
S14	9	S6 AND S11
S15	9	S13 OR S14

? show file

File 2:INSPEC 1969-2003/Apr W2  
(c) 2003 Institution of Electrical Engineers

File 35:Dissertation Abs Online 1861-2003/Mar  
(c) 2003 ProQuest Info&Learning

File 65:Inside Conferences 1993-2003/Apr W3  
(c) 2003 BLDSC all rts. reserv.

File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Mar  
(c) 2003 The HW Wilson Co.

File 233:Internet & Personal Comp. Abs. 1981-2003/Mar  
(c) 2003 Info. Today Inc.

File 474:New York Times Abs 1969-2003/Apr 24  
(c) 2003 The New York Times

File 475:Wall Street Journal Abs 1973-2003/Apr 24  
(c) 2003 The New York Times

File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13  
(c) 2002 The Gale Group

File 256:SoftBase:Reviews,Companies&Prods. 82-2003/Mar  
(c)2003 Info.Sources Inc

File 5:Biosis Previews(R) 1969-2003/Apr W3  
(c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Apr W3  
(c) 2003 Elsevier Science B.V.

File 155:MEDLINE(R) 1966-2003/Apr W3  
(c) format only 2003 The Dialog Corp.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Apr W3  
(c) 2003 Inst for Sci Info

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 1998 Inst for Sci Info

15/5/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

08117586 BIOSIS NO.: 000093116934  
**INTERIM ANALYSES FOR MONITORING CLINICAL TRIALS THAT DO NOT MATERIALLY  
AFFECT THE TYPE I ERROR RATE**  
AUTHOR: GOULD A L  
AUTHOR ADDRESS: MERCK SHARP AND DOHME RES. LAB., WEST POINT, PA. 19486,  
USA.  
JOURNAL: STAT MED 11 (1). 1992. 55-66. 1992  
FULL JOURNAL NAME: Statistics in Medicine  
CODEN: SMEDD  
RECORD TYPE: Abstract  
LANGUAGE: ENGLISH

**ABSTRACT: Monitoring clinical trials** often requires examining the interim findings to see if the **sample** size originally specified in the **protocol** will provide the required power against the null hypothesis when the alternative hypothesis is true, and to increase the sample size if necessary. This paper presents a new method, based on the overall response rate, for carrying out interim power evaluations when the observations have binomial distributions, without unblinding the treatment **assignments** of materially affecting the type I error rate. Simulation study results confirm the performance of the method.

DESCRIPTORS: HUMAN TREATMENT

CONCEPT CODES:

37010 Public Health-Public Health Administration and Statistics  
37012 Public Health-Health Services and Medical Care  
04500 Mathematical Biology and Statistical Methods  
12512 Pathology, General and Miscellaneous-Therapy (1971- )

BIOSYSTEMATIC CODES:

86215 Hominidae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Animals  
Chordates  
Vertebrates  
Mammals  
Primates  
Humans

15/5/2 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

11830278 EMBASE No: 2002406578  
**Home sodium monitoring in patients with diabetes insipidus**  
Green R.P.; Landt M.  
Dr. R.P. Green, One Children's Place, Box 8116, St Louis, MO 63110  
United States  
Journal of Pediatrics ( J. PEDIATR. ) (United States) 01 NOV 2002,  
141/5 (618-624)  
CODEN: JOPDA ISSN: 0022-3476  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 15

Objective: To determine whether home care givers can accurately measure plasma sodium in children with diabetes insipidus (DI) by using an I-STAT portable clinical analyzer (PCA) and to collect preliminary data on home PCA use. Study design: Care givers of 4 children with DI and impaired thirst or inability to access water freely were instructed in PCA use. During an initial preclinical phase, the accuracy of sodium concentration measured by care givers was assessed by comparison to simultaneous analysis in a clinical laboratory. Participants were subsequently randomly assigned to daily home PCA monitoring or routine care. All participants crossed over from their original randomized group **assignment** to the alternate group. Results: After a single education session, all care givers were able to perform PCA testing. There was good correlation between PCA and laboratory sodium ( $r = 0.92$ ). On the basis of Error Grid Analysis, use of the PCA sodium would have resulted in treatment decisions identical to those made based on the laboratory sodium value in 62 of 66 instances. Four minor differences in treatment would have occurred. There was no statistically significant difference in clinical outcome during daily monitoring versus routine care. Conclusions: Results obtained by care givers using the PCA are sufficiently reliable for assessment of fluid status and making treatment decisions.

DEVICE BRAND NAME/MANUFACTURER NAME: Portable Clinical Analyzer/i-STAT/  
United States  
DEVICE MANUFACTURER NAMES: i-STAT/United States  
DRUG DESCRIPTORS:  
\*sodium--endogenous compound--ec  
MEDICAL DESCRIPTORS:  
\*diabetes insipidus  
sodium **blood** level; caregiver; home **monitoring** ; accuracy; device  
infection; **clinical** laboratory; randomization; decision making; outcomes  
**research** ; reliability; human; male; female; case report; clinical trial;  
crossover procedure; child; article; priority journal  
CAS REGISTRY NO.: 7440-23-5 (sodium)  
SECTION HEADINGS:  
007 Pediatrics and Pediatric Surgery  
027 Biophysics, Bioengineering and Medical Instrumentation

15/5/3 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

07276518 EMBASE No: 1998173464  
**A comparison of intravascular pressure monitoring system contamination and patient bacteremia with use of 48- and 72-hour system change intervals**  
McLane C.; Morris L.; Holm K.  
C. McLane, CCRN, 6240 South Rutherford, Chicago, IL 60638 United States  
Heart and Lung: Journal of Acute and Critical Care ( HEART LUNG J. ACUTE CRIT. CARE ) (United States) 1998, 27/3 (200-208)  
CODEN: HELUA ISSN: 0147-9563  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 23

OBJECTIVE: To determine the incidence of culture positivity in intravascular monitoring systems by comparing 48- versus 72-hour intervals for flush solution, stopcocks, and catheters on removal. DESIGN: Prospective, quasi-experimental, random **assignment** . SETTING: Intensive care units of a midwestern university medical center and a community hospital. PATIENTS: Seventy-six critically ill adult patients, ranging in age from 24 to 96 years ( $X = 61.6$ ), requiring arterial or pulmonary artery

catheters. OUTCOME MEASURE: Culture positivity of flush solution, stopcocks, or catheter tips. INTERVENTION: Data collection was initiated at designated change intervals of 48- or 72-hours; cultures were taken of flush solution and stopcocks; catheter tip cultures were obtained on catheter removal. RESULTS: Chi-square analyses indicated that increasing the change interval to 72 hours resulted in no significant difference in culture positivity of catheter tips. However, the difference between the 48- and 72-hour groups in culture-positivity rates of stopcocks from arterial catheters was significant (1, N = 82) = 6.86, p less than 0.01. CONCLUSIONS: Our results showed that increasing the change interval to 72 hours did not increase the risk of catheter-associated infection or catheter-associated bacteremia. Chi-square analysis did not show an association between culture-positive stopcocks, the incidence of culture-positive catheter tips, entries into the system, or catheter-related bacteremia and a change interval that was increased to 72 hours. Thus, increasing the change interval to 72 hours does not increase the risk of infection.

MEDICAL DESCRIPTORS:

\*bacteremia--complication--co; \*bacteremia--diagnosis--di; \*monitor; \*infection--complication--co; \*infection--diagnosis--di  
bacterium culture; incidence; artery catheter; infection risk; bacterium contamination; blood pressure monitoring; human; male; female; major clinical study; clinical trial; randomized controlled trial; controlled study; aged; adult; article; priority journal

SECTION HEADINGS:

004 Microbiology: Bacteriology, Mycology, Parasitology and Virology  
006 Internal Medicine  
027 Biophysics, Bioengineering and Medical Instrumentation  
037 Drug Literature Index

15/5/4 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

06918080 EMBASE No: 1997202542

**Trial of calcium to prevent preeclampsia**

Levine R.J.; Hauth J.C.; Curet L.B.; Sibai B.M.; Catalano P.M.; Morris C.D.; Dersimonian R.; Esterlitz J.R.; Raymond E.G.; Bild D.E.; Clemens J.D.; Cutler J.A.

Dr. R.J. Levine, DESPR, NICHD, National Institutes of Health, Bethesda, MD 20892-7510 United States

New England Journal of Medicine ( NEW ENGL. J. MED. ) (United States)

1997, 337/2 (69-76)

CODEN: NEJMA ISSN: 0028-4793

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 36

Background Previous trials have suggested that calcium supplementation during pregnancy may reduce the risk of preeclampsia. However, differences in study design and a low dietary calcium intake in the populations studied limit acceptance of the data. Methods. We randomly assigned 4589 healthy nulliparous women who were 13 to 21 weeks pregnant to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of

unscheduled outpatient visits and all hospitalizations. Results Calcium supplementation did not significantly reduce the incidence or severity of preeclampsia or delay its onset. Preeclampsia occurred in 158 of the 2295 women in the calcium group (6.9 percent) add 168 of the 2294 women in the placebo group (7.3 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.16). There were no significant differences between the two groups in the prevalence of pregnancy-associated hypertension without preeclampsia (15.3 percent vs. 17.3 percent) or of all hypertensive disorders (22.2 percent vs. 24.6 percent). The mean systolic and diastolic blood pressures during pregnancy were similar in both groups. Calcium did not reduce the numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths; nor did it increase urolithiasis during pregnancy. Conclusions Calcium supplementation during pregnancy did not prevent preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes in healthy nulliparous women.

DRUG DESCRIPTORS:

\*calcium--clinical trial--ct; \*calcium--drug therapy--dt

MEDICAL DESCRIPTORS:

\*calcium intake; \*preeclampsia--prevention--pc; \*preeclampsia--drug therapy--dt

adult; article; blood pressure monitoring ; clinical trial ; controlled study ; diet supplementation; disease severity; female; follow up; human; major clinical study; oral drug administration; prenatal care; priority journal; protein urine level; randomized controlled trial; treatment outcome

CAS REGISTRY NO.: 7440-70-2 (calcium)

SECTION HEADINGS:

010 Obstetrics and Gynecology

037 Drug Literature Index

15/5/5 (Item 4 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

06352968 EMBASE No: 1996017122

**United Kingdom prospective diabetes study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus**

Turner R.; Cull C.; Holman R.

United Kingdom PDSG, Diabetes Research Laboratories, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE United Kingdom

Annals of Internal Medicine ( ANN. INTERN. MED. ) (United States) 1996, 124/1 II (136-145)

CODEN: AIMEA ISSN: 0003-4819

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Purpose: To report the progress (after 9-year follow-up) of a study designed to determine whether improved glucose control in patients with newly diagnosed non-insulin-dependent diabetes mellitus (NIDDM) is effective in reducing the incidence of clinical complications. Data Source: A multicenter, randomized, controlled trial of different therapies for NIDDM. After initial diet therapy, 4209 asymptomatic patients who remained hyperglycemic (fasting plasma glucose levels, 6.0 to 15.0 mmol/L) were assigned to either a conventional therapy policy, primarily with diet alone, or to an intensive therapy policy, aiming for fasting plasma glucose levels of less than 6.0 mmol/L, with assignment to primary therapy with sulfonylurea or insulin (which increased insulin supply) or metformin (which enhanced insulin sensitivity). Results: All three modes of

pharmacologic therapy in the intensively treated group-sulfonylurea, insulin, and metformin-had similar efficacy in reducing the fasting plasma glucose and glycated hemoglobin levels. Over 9 years, patients assigned to intensive therapy with sulfonylurea or insulin had lower fasting plasma glucose levels (median, 7.3 and 9.0 mmol/L, respectively) and lower hemoglobin A(1c) levels (6.7% and 7.5%, respectively) than patients assigned to conventional therapy. Regardless of the assigned therapy, however, the fasting plasma glucose and hemoglobin A(1c) levels increased, and maintaining near-normal glycemia was, in general, not feasible. Even insulin therapy did not achieve the therapeutic goal of near-normal glycemia because of the difficulty in treating marked hyperglycemia and the risk for hypoglycemic episodes. Nine years after the diagnosis of diabetes, 29% of the patients had had a diabetes-related clinical end point, 20% had had a macrovascular complication, and 9% had had a microvascular complication. Conclusions: A report will be published in 1998 after a median duration from randomization of 11 years (range, 6 to 20 years) with an 81% power at a 1% level of significance of detecting whether the obtained improvement in glucose control causes a 15% decrease or increase in the incidence of major complications and whether any specific therapy is advantageous or disadvantageous.

#### DRUG DESCRIPTORS:

\*chlorpropamide--clinical trial--ct; \*chlorpropamide--drug comparison--cm;  
 \*chlorpropamide--drug therapy--dt; \*glibenclamide--clinical trial--ct; \*  
 glibenclamide--drug therapy--dt; \*glibenclamide--drug comparison--cm; \*  
 glipizide--clinical trial--ct; \*glipizide--drug comparison--cm; \*glipizide  
 --drug therapy--dt; \*insulin zinc suspension--drug therapy--dt; \*insulin  
 zinc suspension--drug dose--do; \*insulin zinc suspension--drug combination  
 --cb; \*insulin zinc suspension--clinical trial--ct; \*insulin zinc  
 suspension--drug comparison--cm; \*isophane insulin--clinical trial--ct; \*  
 isophane insulin--drug combination--cb; \*isophane insulin--drug comparison  
 --cm; \*isophane insulin--drug dose--do; \*isophane insulin--drug therapy--dt  
 ; \*metformin--clinical trial--ct; \*metformin--drug combination--cb; \*  
 metformin--drug therapy--dt  
 atenolol--drug therapy--dt; captopril--drug therapy--dt

#### MEDICAL DESCRIPTORS:

\*diabetic angiopathy--complication--co; \*diabetic angiopathy--prevention  
 --pc; \*diabetic nephropathy--prevention--pc; \*diabetic nephropathy  
 --complication--co; \*diabetic retinopathy--prevention--pc; \*diabetic  
 retinopathy--complication--co; \*non insulin dependent diabetes mellitus  
 --epidemiology--ep; \*non insulin dependent diabetes mellitus--drug therapy  
 --dt; \*non insulin dependent diabetes mellitus--therapy--th; \*non insulin  
 dependent diabetes mellitus--etiology--et  
 adult; blood glucose monitoring; clinical trial; conference paper;  
 controlled study; diabetic diet; dose response; drug efficacy; drug  
 potency; female; hemoglobin determination; human; hypertension  
 --complication--co; hypertension--drug therapy--dt; insulin treatment;  
 major clinical study; male; multicenter study; priority journal; randomized  
 controlled trial; treatment outcome; treatment planning  
 CAS REGISTRY NO.: 94-20-2 (chlorpropamide); 10238-21-8 (glibenclamide);  
 29094-61-9 (glipizide); 8049-62-5 (insulin zinc suspension); 9004-17-5  
 (isophane insulin); 1115-70-4, 657-24-9 (metformin); 29122-68-7 (  
 atenolol); 62571-86-2 (captopril)

#### SECTION HEADINGS:

003 Endocrinology  
 012 Ophthalmology  
 018 Cardiovascular Diseases and Cardiovascular Surgery  
 028 Urology and Nephrology  
 037 Drug Literature Index

15/5/6 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

06090308 EMBASE No: 1995120871

**Parent-rated family climate: A concomitant to metabolic control in juvenile IDDM?**

Hansson K.; Ryden O.; Johnsson P.  
Dept. of Child and Youth Psychiatry, University of Lund, P.O. Box  
638, S-22009 Lund Sweden  
Family Systems Medicine ( FAM. SYST. MED. ) (United States) 1994, 12/4  
(405-413)  
CODEN: FSMEE ISSN: 0736-1718  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Parents in 25 families with a diabetic child in poor metabolic control rated their family climate with a **checklist** containing 85 adjectives constituting four climate factors: Closeness, Distance, Expressiveness, and Chaos. Data were obtained before and after one of three treatment conditions: family therapy, pediatric support, and conventional treatment. Data also were obtained from 12 patients in optimal metabolic control and their families, and from 10 reference families with healthy children. Prior to treatment, the parents of children in poor metabolic control rated their family climate as lower on Closeness and higher on Chaos, as compared with the parents of children in optimal control. No differential effects on family climate were found between the family therapy and pediatric support groups. The combined treatment groups rated themselves as higher on Closeness and lower on Chaos after intervention than before. We concluded that parents with children in poor metabolic control normalize their self-treated family climate following family treatment.

**DRUG DESCRIPTORS:**

\*hemoglobin alc--endogenous compound--ec

**MEDICAL DESCRIPTORS:**

\*family life; \*family therapy; \*insulin dependent diabetes mellitus; \*juvenile diabetes mellitus  
adolescent; adult; article; **blood glucose monitoring**; child; child parent relation; **clinical article**; **clinical trial**; conflict; controlled **study**; diabetes control; emotion; female; human; intimacy; male; randomized controlled trial; self concept  
CAS REGISTRY NO.: 62572-11-6 (hemoglobin alc)

**SECTION HEADINGS:**

003 Endocrinology  
006 Internal Medicine  
007 Pediatrics and Pediatric Surgery  
017 Public Health, Social Medical and Epidemiology  
032 Psychiatry

15/5/7 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2003 Elsevier Science B.V. All rts. reserv.

05058449 EMBASE No: 1992198665

**Nonpharmacologic intervention to reduce blood pressure in older patients with mild hypertension**

Applegate W.B.; Miller S.T.; Elam J.T.; Cushman W.C.; El Derwi D.; Brewer A.; Graneý M.J.  
66 N Pauline, Memphis, TN 38105 United States

Archives of Internal Medicine ( ARCH. INTERN. MED. ) (United States)  
1992, 152/6 (1162-1166)  
CODEN: AIMDA ISSN: 0003-9926  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Background. - Although nonpharmacologic interventions are widely recommended in the therapy of high blood pressure in older adults, surprisingly little data exist to confirm the efficacy of these interventions in older persons. Methods. - We conducted a randomized, controlled clinical trial in persons aged 60 to 85 years with a diastolic blood pressure of 85 to 100 mm Hg. The experimental arm was a nonpharmacologic intervention combining weight reduction, sodium restriction, and increased physical activity. The nonpharmacologic intervention consisted of eight weekly group and two individual sessions during the intensive phase, followed by four monthly group sessions during the maintenance phase. The control group received no treatment during the study. Blood pressure was assessed by certified technicians (blinded to group assignment) using random zero sphygmomanometers. Results. - Of 56 participants randomized, 47 completed the entire 6-month trial (21 in the intervention group and 26 in the control group). Attendance at the intervention sessions was excellent. The intervention group lost more weight (-2.1 kg) over 6 months than the control group (+0.3 kg). Trends for decreasing 24-hour urine sodium excretion in both the intervention and control groups, with greater trend in the intervention group, were not statistically significant. The intervention group experienced more reduction in systolic and diastolic blood pressure than did the control group (mean differences between groups at 6 months, 4.2/4.9 mm Hg, respectively). Conclusions. - Our data indicate that a nonpharmacologic intervention will lower systolic and diastolic blood pressure levels in older people with borderline or mild elevations of diastolic blood pressure.

MEDICAL DESCRIPTORS:

\*aging; \*blood pressure regulation; \*hypertension--therapy--th  
adult; aged; article; blood pressure monitoring; clinical article;  
controlled study; diastolic blood pressure; female; human; male;  
physical activity; priority journal; sodium restriction; sodium urine level  
; weight reduction

SECTION HEADINGS:

006 Internal Medicine  
017 Public Health, Social Medical and Epidemiology

15/5/8 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

07350149 92213308 PMID: 1557576

**Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.**

Gould A L

Merck, Sharp, and Dohme Research Laboratories, West Point, PA 19486.

Statistics in medicine (ENGLAND) Jan 15 1992, 11 (1) p55-66, ISSN  
0277-6715 Journal Code: 8215016

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

**Monitoring** clinical trials often requires examining the interim

Bode Akintola 25-Apr-03



findings to see if the **sample** size originally specified in the protocol will provide the required power against the null hypothesis when the alternative hypothesis is true, and to increase the sample size if necessary. This paper presents a new method, based on the overall response rate, for carrying out interim power evaluations when the observations have binomial distributions, without unblinding the treatment **assignments** or materially affecting the type I error rate. Simulation study results confirm the performance of the method.

Tags: Human

Descriptors: \*Clinical Trials--statistics and numerical data--SN; Bias (Epidemiology); Data Interpretation, Statistical; Models, Statistical; Odds Ratio

Record Date Created: 19920504

Record Date Completed: 19920504

15/5/9 (Item 1 from file: 34)

DIALOG(R) File 34:SciSearch(R) Cited Ref Sci

(c) 2003 Inst for Sci Info. All rts. reserv.

01488332 Genuine Article#: HC732 Number of References: 0

(NO REFS KEYED)

**Title: INTERIM ANALYSES FOR MONITORING CLINICAL-TRIALS THAT DO NOT MATERIALLY AFFECT THE TYPE-I ERROR RATE**

Author(s): GOULD AL

Corporate Source: MERCK SHARP & DOHME LTD/W POINT//PA/19486

Journal: STATISTICS IN MEDICINE, 1992, V11, N1 (JAN 15), P55-66

Language: ENGLISH Document Type: ARTICLE

Geographic Location: USA

Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine

Journal Subject Category: MEDICINE, RESEARCH & EXPERIMENTAL; MATHEMATICS, APPLIED; PUBLIC HEALTH

**Abstract: Monitoring clinical trials** often requires examining the interim findings to see if the **sample** size originally specified in the protocol will provide the required power against the null hypothesis when the alternative hypothesis is true, and to increase the sample size if necessary. This paper presents a new method, based on the overall response rate, for carrying out interim power evaluations when the observations have binomial distributions, without unblinding the treatment **assignments** or materially affecting the type I error rate. Simulation study results confirm the performance of the method.